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 This dissertation and the accompanying research is the work of a study designed to 
determine the plausibility of toll-like receptor agonists as an immunotherapeutic for canine 
osteosarcoma.  From a comparative and translational perspective, the long-term goals of this 
research include not only the treatment of canine osteosarcoma, but also human osteosarcoma, as 
this disease has numerous similarities between clinical presentation and progression in both dogs 
and people.  While the translation of our findings into people is far ahead in the future, this 
understanding facilitated our study approach and helped shape it into not only a systematic 
research approach, but also an integrated methodology designed to enhance the likelihood of 
positive outcomes in dogs and possibly even people. 
 Chapter I entails a review of the past and current literature regarding immune interactions 
in canine osteosarcoma, as well as immunotherapeutic strategies investigated for the treatment of 
this canine cancer.  Here we also briefly detail the clinical presentation and progression of canine 
osteosarcoma, along with its similarities to human osteosarcoma. The material reviewed in this 
section create a solid foundation of the current knowledge surrounding canine osteosarcoma and 
the immune system, including the substantial finding that osteosarcoma is an immunogenic tumor 
which can be eliminated by the immune system. 
 Chapter II describes the in vitro studies investigating the dichotomy of toll-like receptor 
expression and functionality between immune and osteosarcoma cell lines of both murine and 
canine origin.   The aims of this study were to identify several toll-like receptor agonists that would 
maximize an anti-tumor immune response, but minimally stimulate osteosarcoma tumorigenesis.  
By investigating mRNA expression levels of a diverse repertoire of toll-like receptors and 
measuring the response of both immune and osteosarcoma cells to treatment with various toll-like 
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receptor agonists, which included read-outs such as cellular viability, cytokine secretion, and pro-
tumorigenic protein upregulation, we were able to identify 3 toll-like receptor agonists 
(Pam3CSK4, Poly(I:C), and CpG ODN 2395) that fit our requirements for immune stimulation 
while minimizing osteosarcoma tumorigenesis. 
 Chapter III investigates the ability of these 3 agonists to reduce osteosarcoma metastatic 
lung tumor burden in a clinically-relevant murine model of osteosarcoma, utilizing the highly 
aggressive K7M2 osteosarcoma cell line.  This model employs tail-vein injection of the neoplastic 
K7M2 cells, which subsequently shower the lungs and consistently replicate the spontaneous 
occurrence of lung metastasis that is deadly in both dogs and people with osteosarcoma.  Here we 
show that the TLR9 agonist CpG ODN 2395 is highly effective at reducing osteosarcoma lung 
metastasis in this model and have also detailed the limitations of this therapy.  In addition, we 
investigate a few of the mechanisms that may underlie CpG ODN 2395’s efficacy. 
 Chapter IV explores the safety of single dose CpG ODN 2395, along with its ability to 
stimulate a measurable immune response in dogs with spontaneous OS in the form of a dose-
escalation pilot study.  Through measurement of circulating cytokine levels and evaluation of 
hematologic parameters, we conclude that a single dose of 2 mg CpG ODN 2395 does stimulate 
an inflammatory response that culminates with evidence of T cell activation, supporting that CpG 
ODN 2395 is immunologically active in osteosarcoma-bearing dogs.  We also report a lack of 
observable toxicities, making CpG ODN 2395 a strong candidate for future clinical trial 
exploration in dogs with spontaneous osteosarcoma.  Chapter V subsequently concludes the 
dissertation and discusses future directions in regard to further evaluation of CpG ODN 2395 as a 
possible osteosarcoma immunotherapeutic. 
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To Gavin, for your unconditional love. 
You will never be “just a dog” to me. 
 
And to all the loved pets who have cancer, 
someone, somewhere is working hard to save you. 
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Osteosarcoma is a malignant mesenchymal neoplasm that accounts for the majority of 
primary bone tumors in dogs and shares biological and clinical similarities with osteosarcoma in 
humans.  Despite dose intensification with conventional cytotoxic therapies, survival times for 
dogs and humans diagnosed with high-grade osteosarcoma have not changed in the past 20 years, 
with the principal cause of mortality being the development of pulmonary metastases.  Given the 
therapeutic plateau reached for delaying metastatic progression with cytotoxic agents, exploration 
of alterative adjuvant therapies for improving management of osteosarcoma micrometastases is 
clinically justified.  Evidence suggests that osteosarcoma is an immunogenic tumor, and 
development of immunotherapies for the treatment of microscopic lung metastases might improve 
long-term outcomes.  
In this review, the history and foundational knowledge of immune interactions to canine 
osteosarcoma are high-lighted.  In parallel, immunotherapeutic strategies that have been explored 
for the treatment of canine osteosarcoma are summarized.  With a greater understanding and 
awareness for how the immune system might be redirected toward combating osteosarcoma 
                                               




metastases, the rational development of diverse immune strategies for managing osteosarcoma 
holds substantial promise for transforming the therapeutic landscape and improving disease 
management in both dogs and human beings. 
 
Introduction 
Dogs are second only to humans in terms of naturally occurring inherited disease, and dogs 
retain breed homogeneity that often mimics certain human demographics such as race or 
geographic phenotypes.1  Dogs also acquire similar genetic diseases and cancers as do people and 
consequently might serve as suitable comparative models for conserved pathologies.1,2  The 
accelerated aging of dogs, especially large breeds in comparison with humans, combined with the 
large numbers of veterinary healthcare dollars spent on dogs (second only to human healthcare 
dollars spent), provide researchers with a relatively large population of pet dogs that might be 
available for the study of cancer pathogenesis, as well as for participation in clinical cancer trials.3,4  
Collectively, the shared genetics of specific canine cancers with their human counterparts and the 
high societal value placed upon dogs as companion animals allow pet dogs to serve as valuable 
large animal models for translational cancer research. 
Osteosarcoma (OS) accounts for 85% of all skeletal tumors in the dog, making it the most 
common primary bone tumor5–9 with an estimated 10,000 dogs diagnosed with OS each year.10  
Histologically, OS is composed of malignant mesenchymal cells of stem cell or osteoblast lineage 
that produce osteoid.  Different histologic subtypes of OS exist including osteoblastic, fibroblastic, 
chondroblastic, and telangiectactic phenotypes, and are based upon the morphology and 
differentiation characteristics of tumor cells.11  Typically, OS is considered a disease of large and 
giant breed dogs12 and it has a predilection to arise from the appendicular skeleton.13,14  Middle-
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aged to older dogs (median age of 7 years) are most commonly affected by OS,5–9,13,15–22 but a 
bimodal age distribution may occur with a smaller peak of OS at 18–24 months of age.18 
Similar to dogs, OS is the most common primary focal skeletal tumor in people and 
accounts for more than 56% of all bone tumors.  In adolescents, OS is the third most frequent cause 
of cancer and often affects taller adolescents, similar to large breed dogs.2  The diagnosis of OS in 
people also follows a bimodal age distribution, but unlike dogs where the incidence of OS is 
highest in older animals, adolescents are affected more frequently in humans.23 
The biologic behavior of OS is aggressive, initially restricted to the local bone 
microenvironment but with distant organ involvement as a result of metastatic disease progression.  
Although only about 15% of dogs and 20% of people present with detectable lung metastases, the 
eventual development of distant metastatic foci in the absence of chemotherapy is 90% within 1 
year for dogs and 80% within 2 years for people.7,10,20,24  Although adjuvant chemotherapy has 
increased the cure rate of people and survival time of dogs diagnosed with high-grade OS, there 
has been no improvement in long-term treatment outcomes in the last 20 years for either species, 
despite the institution of conventional dose intensification strategies.25–28  Based upon the current 
therapeutic ceiling reached, the identification of promising and complementary adjuvant 
treatments for improving the management of micrometastatic disease is clinically warranted. 
Focused scientific development and clinical assessment of novel immunotherapeutic 
strategies are areas that are rapidly gaining momentum in veterinary medicine and in the treatment 
of canine OS (Figure 1.1).  Given the conserved biology of OS between dogs and people, unique 
opportunities exist for veterinary researchers and clinical oncologists to adapt immunobiological 
advances in the human oncology arena for translational purposes in dogs with OS.  Reciprocally, 
novel tumor immunotherapeutic strategies first evaluated in dogs with OS also have the potential 
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to inform and guide development of new treatment regimens for the benefit of human cancer 
patients. 
 
Clinical Evidence of Immunogenicity:  Limb-Spare Infections in Osteosarcoma 
The capacity for the immune system to recognize and eliminate cancer has been recognized 
for over a century with some of the earliest reports including the eradication of bone sarcomas.  In 
the early 1890’s, William Coley reported that accidental acquisition or intentional inoculation of 
the bacterium responsible for erysipelas (Streptococcus pyogenes) could result in regression or 
delayed recurrence of various cancers.29,30  These clinical insights eventually led to Coley’s 
development of a vaccine consisting of 2 killed bacteria, Streptococcus pyogenes and Serratia 
marcescens.31  The vaccine was named “Coley’s Toxins” and was efficacious in the treatment of 
a variety of tumor types, including bone sarcomas.32 
Coley’s observations that underscored the potency of the immune system against cancer 
have been long recognized, but not until recently was direct in vivo evidence regarding infection-
enhanced anti-tumor immunity for OS revisited and reported to the medical community.  Although 
histologic evidence of non-septic, chronic inflammation in biopsy specimens of canine OS has not 
been found to be prognostic,18 spontaneous regression of OS in dogs has been reported33 and dogs 
that experience acute bacterial infection secondary to limb-salvage surgery have been found to 
have increased survival times in several independent studies.34–37  The initial observation of this 
finding was reported in a study investigating the use of radiation therapy before cortical allograft 
limb-sparing surgery in dogs with high-grade appendicular OS.  Although radiotherapy before 
limb-sparing surgery was deemed detrimental for achieving durable fixation of bone allografts, a 
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significant increase in survival time was noted between dogs whose allograft became infected as 
compared to dogs with allografts that remained uninfected (11 versus 5 months, respectively).34 
These initial findings later were corroborated by 2 additional studies that examined the 
outcome of dogs with OS treated with limb-sparing surgery and adjuvant chemotherapy.35,36  Dogs 
with distal radial OS that developed cortical allograft infection were half as likely to die and half 
as likely to develop metastatic disease as compared to dogs without infection, which resulted in a 
significant difference in median survival time (MST) of 18 versus 7.6 months, respectively.35  
Similar findings were reported in dogs undergoing either cortical allograft or endoprosthetic limb-
sparing surgery.36  No difference in MST was found between the 2 surgical groups but MST was 
found to be significantly longer in dogs that experienced construct failure (22.8 versus 10.7 
months) or post-operative infection (22.8 versus 9.6 months).  Dogs with post-operative infection 
also were 25 times less likely to die, and median metastasis-free interval (MFI) was increased for 
dogs with infection (18.5 versus 9.1 months).  All dogs with construct failure also had post-
operative infections, and irritation secondary to construct failure might have contributed to 
infection development.  Lastly, in a recent retrospective study, when evaluating only dogs that 
lived for >1 year after histopathologic diagnosis of OS, increased survival time of dogs that 
developed post-operative limb-spare infections also was identified.  Dogs with limb-spare 
infections had a MST of 6 months beyond 1 year, whereas dogs that underwent limb-sparing 
surgery but did not acquire infection only achieved a MST of 0.9 months beyond 1 year.37 
People with OS who were treated by endoprosthetic replacement and experienced post-
operative infection also had increased survival time.38  A later study, however, found no difference 
in survival time between infected and non-infected patients when matched for type of 
chemotherapy, histologic response, tumor size and location, and local recurrence.39  No case–
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control studies for comparison have been performed in dogs to date, but the majority of studies do 
suggest that non-specific immune stimulation secondary to infection prevents the recurrence or 
delays progression of OS in a clinical setting. 
The immune mechanisms that contribute to increased survival secondary to limb-spare 
infection have not been well-studied, but evidence for innate system involvement on the 
suppression of OS growth has been derived from a murine model of chronic bacterial 
osteomyelitis.  In this study, osteomyelitis decreased tumor growth and increased survival time in 
mice when tumors were established after infection, but this effect was abrogated when tumors 
were established before induction of osteomyelitis.40  Several different types of infectious agents 
have been cultured in affected dogs34–36 and infection-associated inhibition of tumor growth in the 
murine model of chronic bacterial osteomyelitis was not dependent on the specific infectious agent 
involved.  Increased circulating and splenic inflammatory monocytes as well as increased tumor-
associated macrophages (TAM) were observed in infected mice, and depletion of natural killer 
(NK) cells or monocytes and macrophages was found to reverse the tumor growth inhibition seen 
with concurrent osteomyelitis.  These observations led the authors to conclude that both NK cells 
and monocytes and macrophages are associated with the innate anti-tumor response elicited by 
chronic bacterial osteomyelitis, and they speculated that the increase in inflammatory monocytes 
was associated with repopulation of activated TAM, which were expected to be tumor-inhibitory 
in this setting rather than tumor-promoting.  Furthermore, the finding of increased NK cells might 
be related to back-and-forth activation between NK cells and monocytes, also contributing to 
tumor inhibition.40 
These clinical and pre-clinical studies strongly suggest that OS is an immunogenic 
neoplasm, and micrometastatic disease potentially can be controlled or eliminated after recognition 
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by the immune system.  Case–control studies in dogs to either confirm or refute these findings39 
and mechanistic studies to characterize the specific immune responses against OS cells elicited by 
limb-spare infections are lacking. 
 
Humoral Evidence of Immunogenicity 
Cell-Mediated Reactivity and Serum Blocking Activity 
Cell-mediated reactivity (CMR) and serum blocking activity (SBA) experiments were used 
to investigate interactions of the immune system with canine OS.  Simply defined, CMR refers to 
inhibition of target cell growth whereas SBA refers to promotion of target cell growth in the 
presence of serum.  Autologous serum from dogs with progressively growing OS exhibited SBA 
effects in vitro, and decreased CMR was observed when co-cultures of autologous lymphocytes 
and tumor cells were incubated in the presence of the patient’s serum.  In the absence of autologous 
serum, high numbers of lymphocytes could inhibit tumor growth in vitro, whereas low lymphocyte 
numbers conversely stimulated growth.  Based upon these observations, humoral factors present 
in the patient’s serum (e.g., blocking antibodies or antigen-antibody complexes) were surmised to 
prevent tumor destruction by autologous lymphocytes, but other serum-derived factors likely 
potentiated tumor growth.  Whether the SBA was mediated by inhibitory cytokines was not 
considered in these studies.41,42 
Extending upon these initial findings, changes in SBA were investigated pre- and post-
operatively in dogs with OS that underwent amputation of the tumor-bearing limb.  Increased pre-
surgical SBA was noted in dogs that eventually developed metastatic disease, and post-surgical 
SBA increased before development of overt metastatic disease in the majority of dogs (6/8, 75%). 
For dogs remaining free of metastasis, SBA was unmeasurable.43  In a complementary study, post-
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surgical SBA in dogs with OS given Bacillus Calmette-Guerin (BCG) intradermally also was 
found to increase in conjunction with radiographic appearance of metastasis.44  Based upon these 
findings, SBA was proposed to be of potential value for determining prognosis, but identification 
of specific factors mediating SBA (e.g., antibodies or inhibitory cytokines) was not determined in 
these studies.43 
 
C1q Binding Levels 
The C1q-binding test is used in immunology to evaluate circulating immune complexes 
(CIC). A single study evaluated serum C1q-binding levels in dogs with OS, and demonstrated that 
a large percentage of dogs (46/ 56, 82%) had increased C1q-binding at the time of diagnosis.  In a 
subset of dogs (n = 12) in which serial C1q-binding levels were available for quantification, 
divergent trends in C1q-binding levels were observed based upon disease status.  In dogs that 
survived up to 1 year post-diagnosis (n = 4), the C1q-binding levels where found to have fallen 
within normal reference ranges after completion of therapy.  Conversely, in dogs that experienced 
local disease recurrence or distant metastases (n = 8), levels of C1q-binding either remained 
increased throughout the entire study duration or only transiently decreased before increasing 
again.  The CIC identified in these dogs had characteristics consistent with IgG, but this conclusion 
was made cautiously because anomalous fractionation results were observed in normal control 
dogs.45 
 
TP-1 and TP-3 Antibodies 
TP-1 and TP-3 are murine anti-human monoclonal antibodies (mAbs) created using the 
hybridoma technique by immunization of mice with human OS cells.  These 2 distinct mAbs bind 
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different epitopes of the same unknown antigen and have been shown to be highly sensitive and 
moderately specific for human OS.  Using immunohistochemistry (IHC) on canine tumor tissues, 
the TP-1 and TP-3 antibodies also were shown to have useful specificity for canine OS, although 
chondrosarcomas and several carcinomas were cross-reactive with these antibodies.  Staining of 
normal canine tissues with these antibodies was limited.46  Extending upon the recognition of 
conserved epitopes in formalin-fixed tissues, additional studies in OS dogs with 131I- or 123I-labeled 
F(ab')2 fragments of TP-1 or 18F-labeled TP-3 Fab fragments showed high specificity of these 
antibodies for primary and metastatic OS lesions using immunoscintigraphy and positron emission 
tomography (PET) scanning, respectively.47,48  Immunoscintigraphic evaluation of I-labeled 
F(ab')2 fragments of TP-1 also detected multiple metastatic lesions that were not detectable by 
conventional radiography.47  Despite the sensitivity and specificity of TP-1 and TP-3 antibodies 
for conserved OS epitopes, use of these antibodies for diagnostic purposes, either for IHC or 
molecular imaging, is limited in both human and veterinary medicine, and likely stems from a lack 
of commercial availability.  Nonetheless, cross-reactivity of TP-1 and TP-3 antibodies for 
conserved OS epitopes in canine tumor tissues further supports the capacity for immune 
recognition of canine OS antigens. 
 
Negative Cellular and Soluble Regulators:  Evidence for Immune Evasion 
Regulatory T-cells 
Regulatory T-cells (Tregs) are a component of the immune system responsible for 
controlling and suppressing excessive immune activation.  Phenotypic characterization of Tregs 
includes concurrent expression of CD4 and CD25 surface antigens along with transcription of the 
FoxP3 gene.  Dysregulation of Tregs has been incriminated in the induction of autoimmunity, and 
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conversely promotion of ineffective anti-tumor immunity.  Given the potential role of Tregs in 
suppressing the immune surveillance of cancer, Tregs have been investigated in dogs with cancer 
and specifically in dogs with OS.  Several studies have documented increased expression of 
CD4+FoxP3+ Tregs in dogs with cancer compared to controls, findings that suggest potential 
participation of Treg-induced immune suppression and cancer progression.  When stratified by 
tumor histology, no difference in the percentage or absolute number of Tregs was identified between 
OS-bearing and normal dogs in either peripheral blood or draining lymph nodes, but the small 
sample sizes of dogs with OS used for comparison might have limited the power to detect the 
existence of a true difference between groups.49,50  A later study examining only dogs diagnosed 
with OS and free of measurable metastatic disease also confirmed no difference between peripheral 
blood or lymph node CD4+CD25+FoxP3+ Treg numbers when compared to healthy controls.  In 
fact, Treg numbers were found to be significantly lower in the tumor-draining nodes when 
compared to non-draining nodes of the OS dogs.51 
Discordant with the findings derived from other investigations, differences in Tregs were 
identified in another study that evaluated dogs with OS that had not received chemotherapy within 
3 weeks of blood collection.  Significantly increased numbers of relative and absolute circulating 
CD4+FoxP3+ Tregs were identified in OS dogs versus control dogs.  Despite differences in Tregs 
identified in the blood, similar differences between OS-bearing and normal dogs were not 
identified when Tregs were evaluated in draining or non-draining lymph nodes.  Additionally, no 
differences in circulating Tregs were noted between pre- and post-amputation blood samples. 
Concordant changes in effector T lymphocyte populations also were examined, and decreased 
numbers of circulating CD8+ cells (absolute and relative) as well as a decreased CD8+:Treg ratio 
were observed in dogs with OS.  The effector to regulatory T lymphocyte ratio provided prognostic 
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information, with a low CD8+:Treg ratio being associated with decreased survival as compared to 
a high ratio.52 
 
Myeloid-Derived Suppressor Cells 
Myeloid-derived suppressor cells (MDSCs) are immature cells of myeloid lineage derived 
from bone marrow progenitor cells.  In diseases such as cancer, MDSCs are increased and 
contribute to a global immunosuppressive state.  In veterinary medicine, the identification of 
MDSCs as a small percentage of circulating white blood cells in normal dogs and tumor-bearing 
dogs has been possible using flow cytometry.  In 1 study, the percentages of circulating putative 
MDSCs identified by CD11blow and CADO48Alow surface expression were quantitatively different 
between normal healthy dogs and dogs diagnosed with different tumor types including OS.53 A 
higher percentage of MDSCs was identified in tumor-bearing dogs (7.9%) compared to normal 
dogs (3.6%), and in vitro generated MDSCs possessed the capacity to suppress concanavalin A-
induced splenocyte proliferation.  In a complementary study, granulocytic MDSCs were identified 
by CD11b+CD14-MHCII- surface expression in healthy dogs, dogs with early stage non-metastatic 
cancers, and dogs with advance stage metastatic cancers.54 In dogs with advance stage metastatic 
cancers, which included OS and hemangiosarcoma, the percentage of circulating MDSCs was 
significantly higher than in healthy dogs and those with early stage non-metastatic cancers. 
Similarly, isolated MDSCs exhibited immunosuppressive activity as demonstrated by attenuation 
of concanavalin A and human recombinant IL-2 (hrIL-2)-stimulated T cell proliferation.  Based 
on these 2 investigations, evidence was generated to substantiate the existence of MDSCs in dogs, 
both in health and disease.  Importantly, both studies identified increases in the percentage of 
circulating MDSCs in dogs diagnosed with highly metastatic tumors such as OS. 
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Despite their proven existence in dogs with cancer, MDSCs have not been definitively 
identified to play a role in the progression of canine OS.  They have been speculated, however, to 
exert some form of negative immunomodulation in dogs with OS, because dogs with monocyte 
counts >0.4x103 cells/µL have a shorter median disease-free interval (DFI) (6.7 versus 15.5 
months).  In the majority of dogs evaluated (59/69, 86%) this monocyte count did not represent a 
monocytosis, and monocyte numbers were still within the reference interval.55 In a study 
investigating prognostic factors in dogs with OS of the maxilla, mandible, or calvarium, there was 
also a significantly increased hazard of death with increasing monocyte count.56 
 
Tumor-Derived Soluble Factors 
Tumor-derived soluble factors (TDSFs) produced from 2 immortalized canine OS cell lines 
(OSA8 and OSA16) have been shown to suppress the function of cultured canine myeloid cells.  
Co-culture of canine dendritic cells, macrophages, or both with tumor-conditioned media (TCM) 
containing TDSFs suppressed activation of these antigen-presenting cells by decreased expression 
of MHC Class II and CD80 (B7.1), decreased phagocytic activity, and decreased capability to 
induce splenic effector cell proliferation.57 
 
Immunotherapeutics:  Historical and Current Strategies 
Bacillus Calmette-Guerin 
Although utilized for vaccination against tuberculosis since the 1920’s,58 Bacillus 
Calmette-Guerin (BCG) immunotherapy also has been investigated since the 1930’s as an anti-
tumor immune modulator after the observation that people who died from tuberculosis 
coincidently also had a decreased incidence of cancer.  Broad anti-tumor immune activity elicited 
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by BCG has been demonstrated in several murine tumor model systems, as well as in various 
naturally occurring tumor types including stomach cancer, melanoma, and leukemia.  Today, 
BCG’s principal anti-cancer immunotherapeutic role is for the treatment of non-muscle invasive 
bladder cancer in people.59 In the setting of bladder cancer, BCG is believed to exert its 
immunobiologic effects by upregulation of MHC II molecules in malignant transitional epithelial 
cells, along with the induction of CD4+ Th1 and cytotoxic T lymphocyte (CTL) responses.60 
The exploration of BCG immunotherapy for canine OS began in the early 1970’s.  Initially, 
injection of BCG either IV, intraperitoneal, or intrathoracic into normal dogs was performed to 
investigate the capacity of BCG to create pathologic lesions.  Histologically, BCG injections 
generated granuloma formation within the liver and lung parenchyma, along with lymphoid 
hyperplasia of the tonsils and bronchial lymph nodes.  Positive tuberculin test reactions were noted 
most often in dogs receiving intrathoracic BCG.  Subsequently, dogs with spontaneous OS, the 
majority of which did not have evidence of metastatic disease, were given IV BCG at variable 
intervals, with or without concurrent vaccination with irradiated autologous tumor cells.  Findings 
derived from these OS-bearing dogs receiving BCG indicated no enhancement of metastasis, but 
instead a possible delay in metastatic development and progression, conclusions that were 
substantiated by longer survival times in dogs that received BCG as compared with a historical 
control group.61  Another study reported findings derived only from dogs with OS that underwent 
amputation (n = 12) and that received an identical BCG IV injection scheme, with or without 
irradiated autologous tumor cells.62  This study noted a significant increase in survival compared 
to a previously published historical control group (51 versus 14 weeks).62 Interestingly, 
improvements in survival times were not restricted by the route (IV) of BCG administration, and 
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intradermal delivery of BCG to dogs with OS after amputation also significantly extended survival 
to 40 weeks versus 13 weeks for controls.44 
After documented clinical activity in dogs with OS, mechanistic studies were conducted to 
characterize the potential mode of action of BCG.  Studies conducted in normal and tumor-bearing 
dogs demonstrated that BCG administration could stimulate alveolar macrophage activity and 
promote lymphocyte cytotoxicity ex vivo.  Not surprisingly, the anti-tumor cytotoxicity induced 
by BCG was observed to be non-specific with lysis of several tumor types in addition to OS, 
including melanoma and mammary carcinomas.63-65  Non-specific cytotoxicity exerted by BCG-
primed alveolar macrophages and lymphocytes against multiple cancer cell lines was suspected to 
be the result of shared tumor cell antigens or polyclonal lymphocyte activation.63  Given its 
capacity to induce granuloma formation, BCG’s immunobiologic effects could be associated with 
activation of circulating monocytes or tissue macrophages in reticuloendothelial organs. 
Specifically, CCR2+ inflammatory monocytes that expand within the marginal zone of the spleen 
have been associated with cross-presentation of tumor antigens and subsequent tolerance of CD8+ 
memory T-cells, whereby splenectomy restores lymphocyte and antitumor function.66  As such, 
the effect of splenectomy was evaluated in dogs with OS treated with amputation and 
administration of an intra-dermal methanol-extracted residue of BCG (MER).67  Unexpectedly, 
splenectomy led to decreased survival in the OS dogs, whereas dogs treated with amputation and 
MER without splenectomy had similar survival times to historical controls.67 
 
Muramyl Peptides 
The muramyl peptides include muramyl dipeptide phosphatidylethanolamine (MDP), a 
synthetic analog of the peptidoglycan cell wall of mycobacteria that is the smallest part of 
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mycobacteria that is immunostimulatory, and muramyl tripeptide phosphatidylethanolamine 
(MTP-PE), a lipophilic derivative of MDP.68,69  The liposomal form of MTP (L-MTP-PE) can be 
used for the in vivo stimulation of macrophages and monocytes rendering them cytotoxic against 
tumor cells, but L-MTP-PE itself does not exert any direct tumor cytotoxic properties.70,71  These 
unique features make LMTP-PE an ideal candidate for the immunotherapy of cancer, and in 
people, L-MTP-PE has resulted in prolonged survival in patients with OS in both initial and 
relapsed settings.72-73 
In the context of canine OS, the in vitro incubation of canine peripheral blood mononuclear 
cells (PBMCs) with MDP was shown to elicit cytostasis against the D-17 cell line, and this 
cytostatic effect was maximized by a combination of MDP and lipopolysaccharide (LPS) 
compared to either agent used alone.74  This maximal effect of MDP and LPS was identified to be 
secondary to TNFα secretion and not because of direct toxicity induced by MDP or the 
combination of MDP and LPS.75  Correlating with cell culture experiments, PBMCs collected from 
healthy dogs after IV L-MTP-PE administration also had significantly more cytostatic activity 
against the D-17 line, and serum harvested from the same dogs had increased TNFα activity within 
2 hours after L-MTP-PE injection.74-75 
In addition to evaluating the anti-cancer effects of L-MTP-PE as a single agent, a 
combination of L-MTP-PE and doxorubicin chemotherapy also was investigated in vitro and in 
vivo, and indicated that a combination of doxorubicin and L-MTP-PE enhanced PBMC activation 
and cytotoxicity compared to either drug alone.  Again, the observed biologic response was 
mediated by TNFα.76 Given the predilection of OS to metastasize to the pulmonary parenchyma, 
a similar combination platform was investigated for the activation of canine pulmonary alveolar 
macrophages against D-17 cells.  Similar to the results generated by PBMCs, pulmonary alveolar 
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macrophages harvested from dogs receiving combination therapy with doxorubicin and L-MTP-
PE exerted the greatest ex vivo cytotoxicity against canine OS target cells.77 
The translational relevance of the observed in vitro and ex vivo activity of L-MTP-PE 
against canine OS cells has been investigated in dogs with spontaneously occurring OS.  In the 
first reported study of L-MTP-PE in dogs with OS, the anti-cancer activity induced by IV L-MTP-
PE as a single agent was evaluated by a randomized, placebo-controlled trial.  In comparison with 
placebo controls, dogs treated with amputation and twice weekly IV L-MTP-PE had significant 
extensions of MST (222 versus 77 days) and median MFI (168 versus 58 days).78 Despite the 
substantial improvement in survival times induced by single agent L-MTP-PE, over 50% of the 
dogs studied ultimately experienced metastatic progression and were dead by 8 months after 
therapy.  In an attempt to improve long-term survival in dogs with OS treated with L-MTP-PE, a 
subsequent study evaluated the use of L-MTP-PE in combination with adjuvant cisplatin 
chemotherapy in dogs without macroscopic metastatic disease.  When used in combination 
serially, administration of L-MTP-PE after amputation and cisplatin chemotherapy significantly 
prolonged MST (14.4 versus 11.2 months) and median DFI (9.8 versus 7.6 months).  However, if 
L-MTP-PE was given concurrently with cisplatin chemotherapy in the adjuvant setting, no survival 
benefit was identified beyond that achieved with cisplatin chemotherapy alone.79  Given that L-
MTP-PE failed to be approved by the US Food and Drug Administration in 2007 for the initial 
treatment of non-metastatic OS in children, clinical research with muramyl peptides for the 
treatment of OS in dogs has not advanced during the past decade, and L-MTP-PE will not likely 
be available in the United States for the management of OS in dogs.  In contrast, L-MTP-PE is 




Interleukin-2 Cytokine Therapies 
Interleukin-2 (IL-2) is a pleiotropic cytokine responsible for several key immune responses 
including differentiation and subsequent expansion of activated T cells into effector and memory 
T cells after stimulation by immunogenic antigens.  Given the potent role of IL-2 for establishing 
cell-mediated immune responses, IL-2 has been investigated both ex vivo and in vivo for the 
management of canine OS.  In an early study, the ability of hrIL-2 to activate peripheral blood 
leukocytes (PBL) derived from either normal dogs or dogs with lung tumors was investigated in 
vitro.  When derived from dogs with lung tumors, autologous stimulated lymphocytes (ASL) 
generated by culture with hrIL-2 and phytohemagglutinin (PHA) were significantly more cytotoxic 
against autologous tumor cells when compared with ASL produced from healthy dogs.  These 
findings suggested that hrIL-2 could preferentially reactivate ASL collected from tumor-bearing 
dogs to exert cytotoxicity against naturally occurring pulmonary tumors, including metastatic OS.  
In addition, increased ASL cytotoxicity in tumor-bearing dogs compared to healthy dogs could 
indicate that tumor-bearing dogs had tumor-specific lymphocytes.80 In a separate study in which 
healthy beagle dogs were given continuous IV IL-2 via the splenic artery or inferior vena cava, the 
generation and cytotoxicity of lymphokine-activated killer (LAK) cells derived from PBL against 
the canine D-17 OS cell line was evaluated.  Splenic artery infusion of IL-2 was consistently 
observed to stimulate LAK cell activity in PBL, whereas inferior cava infusion did not.  The spleen 
also underwent “lymphoblastic change” with splenic artery infusion, which consisted of marked 
lymphoid proliferation with loss of normal splenic architecture, supporting that the more robust 
LAK activity seen in these dogs was directly related to splenic immunostimulation.81 Although 
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this study evaluated D-17 OS cells as the target cells of LAK activity, it was not further determined 
if the LAK activity generated was specific for OS or a non-specific tumor response. 
Several studies evaluating the immunobiologic activities of IL-2 administration in vivo 
have been conducted and focused on direct delivery of IL-2 or the transgene expression of IL-2 in 
the lungs of healthy dogs and in dogs with metastatic OS.  Nebulization of liposomal hrIL-2 in 
healthy dogs was shown to activate cytolytic and cytostatic activity of bronchoalveolar lavage 
(BAL) leukocytes, as well as increased total BAL leukocyte numbers with concurrent increases in 
the lymphocyte and eosinophil percentages.  Additionally, nebulized liposomal hrIL-2 was 
determined to be safe with no life-threatening adverse systemic reactions noted.82 When evaluated 
in a clinical trial of dogs with primary lung tumors or lung metastases, treatment with liposomal 
hrIL-2 nebulization resulted in 2 of 4 dogs with OS lung metastases experiencing complete 
regression of all metastatic lesions (lung or lung and lymph node) for >1 year.  Interestingly, 
liposomal hrIL-2 nebulization failed to generate uniform responses in dogs with metastatic OS, 
with the other 50% of dogs experiencing progressive disease.  Correlating with the observed 
clinical responses, immunobiologic activity of liposomal hrIL-2 nebulization was supported in 
tumor-bearing dogs by augmentation in BAL leukocyte numbers, percentages, and cytolytic 
activities.  Additionally, an increase in T lymphocytes and a shift in the CD4:CD8 ratio because 
of increased CD4+ cells was observed in dogs receiving hrIL-2 nebulization.  Ultimately, all dogs 
developed neutralizing antibodies against hrIL-2, limiting application of this immunostimulatory 
strategy to short-term use in a clinical setting.83 
In an effort to localize IL-2 preferentially to the lung parenchyma without the need for 
aerosolization as well as to avoid neutralizing antibody formation, IV administration of cationic 
liposome-DNA complexes (LDCs) containing canine IL-2 cDNA also has been explored in dogs 
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with metastatic lung OS (n = 20), with the intent to induce lung-specific IL-2 transgene expression 
and immunomodulation.  Increased NK cell activation, along with increased monocyte expression 
of MHC Class II and B7.2 (CD86) were observed in this study, indicating the enhancement of 
immunobiologic activities by LDCs.  The LDCs were primarily taken up by CD11b+ monocytes 
rather than lymphocytes, suggesting that LDCs along with transcription of IL-2 itself both 
contributed to a systemic, innate immune response.  In 3/20 (15%) dogs treated with LDCs, 
complete or partial regression of lung metastases was observed and 4/20 (20%) dogs experienced 
disease stabilization.  Overall survival time compared to historical controls matched for age and 
tumor stage also was marginally increased (MST of 2.7 versus 2 months).84 
Although these 2 in vivo studies exploring IL-2 cytokine strategies identified only modest 
clinical benefits, the data do provide evidence supporting the feasibility of targeted, lung-specific 
immunotherapy for the treatment of macroscopic OS pulmonary metastases.  Presumably, IL-2 
cytokine therapy would be expected to exert greater therapeutic benefit in a microscopic residual 
disease setting. 
 
Adoptive Transfer of T cells 
Only a few studies have investigated the use of adoptive T cell transfer in dogs with OS.  
One investigation evaluated the feasibility, toxicity, and therapeutic outcome associated with IV 
infusion of the human cytotoxic T cell line, TALL-104, to dogs with OS.  In this study, dogs with 
appendicular OS were treated with surgery and adjuvant cisplatin chemotherapy, and if remaining 
free of pulmonary metastases at the completion of chemotherapy, subsequently were given IV 
infusions of TALL-104 monthly for up to 9 consecutive months.  Collectively, combination 
therapy inclusive of surgery, cisplatin chemotherapy, and adjuvant TALL-104 was tolerable and 
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allowed OS-bearing dogs to achieve MSTs and DFIs of 11.5 and 9.8 months, respectively, which 
is comparable to dogs treated with combined surgery and chemotherapy.  As expected, the 
xenogeneic nature of TALL-104 caused dogs to develop antibodies and a cellular immune 
response against TALL-104 with generation of a long-lived, neutralizing antibody response in 
some dogs.  Mechanistically, anti-cancer activities exerted by TALL-104 were believed to be 
principally mediated by endogenous anti-tumor immunity and partially by MHC-independent NK 
cell cytotoxicity, as supported by an ex vivo 51Cr-release assay conducted in dogs before relapse.85 
With unprecedented advances in immunobiological techniques, it recently has become 
possible to create engineered T cells that express stable chimeric antigen receptors (CARs) with 
specificity against a myriad of targetable epitopes, thereby allowing for the immunologic 
recognition and treatment of different types of cancer.  Recently, protocols have been optimized 
to allow for the generation of canine T cells expressing CARs for HER2, a membrane protein 
expressed in canine OS.  Preliminary results indicate that canine T cells with CARs specific for 
HER2 possess the capacity to kill HER2+ canine OS cells in an antigen-dependent manner.86  
Based upon these promising early results, additional studies utilizing molecular CAR technologies 
for the treatment of dogs with OS are anticipated. 
 
Fas Receptor and Fas Ligand Signaling 
Induction of apoptosis is one way the immune system can eliminate cancer cells.  
Mechanistically, cytotoxic T cells or NK cells can trigger programmed cell death in targeted cells 
by the coordinated release of perforin and granzyme after appropriate cellular recognition cues.  
However, all too often, this form of direct apoptosis induction by the immune system can be evaded 
by cancer cells through their acquisition of genetic mutations.  Rather than relying directly on 
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immune cell induction of apoptosis by cytotoxic T cells, NK activation, or both, investigators have 
evaluated the ability to induce apoptosis in cancer by indirect mechanisms.  One strategy for 
augmenting immune-mediated apoptosis in cancer cells has been through manipulation of the Fas 
receptor (Fas) and Fas ligand (FasL) signaling pathway. 
Fas-dependent apoptosis is mediated through the binding of FasL, expressed by immune 
effector cells, with cognate Fas receptor expressed on the surface of target cancer cells.  Binding 
of FasL with the Fas receptor results in clustering of intracytoplasmic death domains and 
consequent cleavage of initiator procaspases by proximity-mediated activation.  In the context of 
clonal evolution, tumor cells would favor the loss of Fas receptor expression with consequent 
enrichment of tumor cell populations inherently resistant to Fas-mediated cell death.  In support 
of such a resistance mechanism, lung metastases in people with OS often fail to express the Fas 
receptor, in contrast with the primary tumors which are Fas+.87  Additionally, preclinical murine 
models of OS recapitulate this immune evasive phenomena, with the expression of Fas receptor 
being lost during OS metastasis, which allows metastatic lesions to circumvent the induction of 
apoptosis by FasL-expressing effector immune cells, as well as the constitutive cellular expression 
of FasL within lung tissue.87,88 
Given the apparent importance of Fas-mediated signaling in the immune surveillance of 
OS metastases, strategies that modulate the expression of Fas or FasL might augment anti-tumor 
immune responses.  In one study, neoadjuvant FasL gene therapy using an adenovirus vector (Ad-
FasL) was delivered to primary bone tumors in dogs with appendicular OS to augment intra-
tumoral apoptosis, inflammation, and consequent innate immune responses.  In this study, dogs 
were given a single dose of Ad-FasL, which was followed by a 10-day waiting period after which 
the dogs underwent amputation of the affected limb.  Improved survival was appreciated in dogs 
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whose tumors had inflammation or lymphocyte-infiltration scores of  >1 and in dogs with 
apoptosis scores (via cleaved caspase-3 IHC) in the upper 50th percentile.  Additionally, decreased 
tumor Fas expression was associated with increased inflammation, DFI, and MST.89 
Derived from preclinical murine studies indicating that gemcitabine (a deoxycytidine 
analogue) could cause apoptosis of OS cells through Fas/FasL interactions, a study evaluating the 
tolerability and anti-cancer activity of aerosol gemcitabine in dogs with OS was conducted.  In this 
study, gemcitabine caused increased apoptosis as measured by terminal deoxynucleotidyl 
transferase-mediated dUTP nick end-labeling (TUNEL) and marked necrosis within lung 
metastatic lesions.  Metastatic foci of gemcitabine-treated dogs also had increased Fas expression 
compared to the primary tumor and also when compared to controls, suggesting gemcitabine 
therapy reverses the down regulation of Fas that is often recognized in metastatic OS lesions.  
Despite evidence for beneficial immunomodulatory changes induced by gemcitabine 
aerosolization, little clinical benefit was detected in treated dogs, with median DFI and overall 
survival time being comparable with historical controls.90 
 
Therapeutic Tumor Vaccines 
Recently, various tumor vaccine platforms have been investigated as novel treatment 
strategies for improving the management of diverse tumor types including canine OS.  In one study 
intended to augment innate immune responses generated within the tumor microenvironment, an 
IV, attenuated Salmonella typhimurium (VNP20009) that preferentially localizes and proliferates 
within tumor tissues, was evaluated in a limited number of dogs with OS (n = 4) and produced 
modest anti-cancer activities as indicated by a partial response achieved in one dog.  Despite some 
evidence of anti-tumor immune activation, numerous adverse effects also were noted in this study, 
 23 
limiting the use of VNP20009 to primarily a research setting.91 In addition to a bacterial agent for 
enhancing immune responses to OS cells, an oncolytic vaccinia virus (strain LIVP6.1.1) also was 
successfully tested in vitro for its ability to lyse D-17 cells.  Although the oncolytic vaccinia virus 
strategy produced potent localized innate immune responses in murine xenograft models,92 the 
translational evaluation of such oncolytic viral strategies has yet to be reported in dogs with OS. 
Sophisticated combination cytokine vaccine strategies have been evaluated in dogs with 
OS and have produced early evidence of activity.  In one study, the effects of vaccination with 
irradiated autologous or allogeneic OS tumor cells with xenogeneic cytokine-producing cells 
(hGM-CSF and hIL-2) administered subcutaneously plus suicide-gene therapy with ganciclovir 
(GCV) delivered either intratumorally or peritumorally was evaluated in dogs with appendicular 
or axial OS (n = 5).  To stimulate a robust innate immune response, the combination vaccine 
strategy incorporated a herpes simplex virus thymidine kinase (HSVtk) suicide gene that had been 
shown to sensitize transfected cells to GCV.  Clinically, the combination cytokine vaccine strategy 
exerted modest anti-tumor activities, with 1 dog with appendicular OS achieving a partial response, 
and 2 dogs with axial OS maintaining stable disease.  Survival time for the 5 OS dogs ranged from 
96 to >386 days, with most dogs living <1 year.93 
A recent pilot study in healthy beagle dogs investigated the ability of a dual vaccination 
platform comprised of DNA electroporation and adenovirus serotype 6 (Ad6) for the induction of 
an immune response against 2 potential targetable tumor-associated antigens, telomerase (TERT), 
or HER2/neu.  Both vaccines were found to induce polyspecific T cell responses, supporting the 
ability of the vaccines to elicit quantifiable immune activation, and the TERT vaccine was found 
to significantly increase the number of CD8+ cells.  These immune responses were induced with 
just one injection but could be maintained over time with repeated injections.94 
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With the demonstration that immune responses could be generated in healthy dogs against 
HER2/Neu, another group has adopted an innovative approach to test if clinically relevant immune 
responses can be evoked against HER2/Neu-expressing canine OS cells, with a resultant delay in 
micrometastatic disease progression in dogs with OS.  Through the use of a recombinant 
HER2/neu-expressing Listeria monocytogenes vaccine, preliminary results have been promising 
with increased survival times in dogs receiving Listeria monocytogenes vaccination in comparison 
with historical controls (N. M., personal communication).  Although early in its clinical assessment 
in dogs with micrometastatic OS, the reported findings generated by the investigational Listeria 
monocytogenes vaccine raise exciting possibilities for the future of therapeutic vaccination as a 




A large body of scientific and clinical evidence exists supporting the immunogenicity of 
canine OS.  Given the therapeutic plateau reached with conventional cytotoxic therapies for the 
management of bone sarcomas in both dogs and people, substantive impetus exists for the focused 
development and validation of innovative immunotherapeutic platforms for improving long-term 
disease management.  Although new immunotherapeutic platforms potentially could emerge as 
potent single-agent therapies for canine OS, adjuvant or combination therapies employing both 
immunotherapy and cytotoxic chemotherapy also could create substantial impact in the therapeutic 
management of canine OS.  Many of the immunotherapies currently investigated have indicated 
only limited capacity to substantially extend survival time compared to standard treatment or are 
still in preliminary phases of testing.  Nonetheless, continued research in how to best harness the 
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immune system to combat OS micrometastatic disease remains a highly desirable treatment 




























Figure 1.1:  General categories of anti-tumor immunotherapy (clockwise from top). 
Monoclonal antibodies (mAbs) can be used directly against tumor cells or targeted towards the 
tumor microenvironment.  Direct killing of tumor cells via mAbs is typically through receptor 
antagonist or agonist activity, but can also target enzymatic activities within the tumor cells.  
Conjugation of cytotoxic drugs to mAbs is another mechanism of direct tumor killing. These 
mechanisms can also be applied to the tumor microenvironment.  Enhanced immune-mediated 
killing of tumor cells can also be harnessed through mAbs via enhancement of phagocytosis, 
antibody-dependent cellular cytotoxicity (ADCC), complement activation, or T cell cross-
presentation and activation.  Adoptive transfer of T cells specific for certain tumor cell antigens 
can enhance anti-tumor immunity.  T cells can be genetically engineered to express T cell receptors 
that recognize specific tumor cell antigens or tumor-specific autologous T cells can be isolated 
from the tumor itself with subsequent expansion and reinfusion into the host for the exertion of 
therapeutic activities.  Therapeutic vaccination is aimed at redirecting or enhancing immune 
responses to tumors.  Some therapeutic vaccines employ ex vivo expansion of autologous antigen-
presenting cells (APC) with a common tumor antigen or focus on the modification of tumor cells 
to express or secrete cytokines that enhance APC activation; in both situations these cells are 
reinfused into the patient.  Other therapeutic vaccines focus on delivery of a specific protein that 
is overexpressed by the tumor of interest or serves a specific immune function, delivery of an 
infectious agent to enhance general anti-tumor immunity, or a combination thereof.  Cytokine 
therapies, such as IL-2 or the interferons, can be used in vivo to enhance immune responses, but 
can also be employed in the ex vivo expansion of immune cells for cell-based therapies.  
Modulation of immune signaling with agents such as BCG and muramyl peptides refers to 
enhancement of beneficial anti-tumor immune responses or blockade of immunosuppressive 
signaling.  Manipulation of tumor cells to express costimulatory molecules can enhance immune 
activation, while blockade of inhibitory immune cells (such as Tregs or MDSCs) or inhibitory 
immune receptors (such as CTLA-4) can prevent tumor-based immunosuppression.  Activation 
of innate immune cells, such as dendritic cells, can be achieved through ex vivo cytokine 
activation, in vivo treatment with toll-like receptor ligands or targeted antigen-loaded antibodies, 
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CHARACTERIZING THE EXPRESSION AND FUNCTIONALITY OF TOLL-LIKE 
RECEPTORS IN IMMUNE AND OSTEOSARCOMA CELL LINES 
 
Abstract 
 Toll-like receptors (TLRs) are considered the critical bridge between the innate and 
adaptive immune system.  Investigations surrounding TLRs and their respective agonists in regard 
to cancer-based immunotherapy is not new.  Indeed, TLRs have shown to function in both pro- 
and anti-tumorigenic capacities depending on the specific tumor histology investigated, showing 
the dichotomous nature of how these receptors influence cancer.  However, little research into 
TLRs for the treatment of either human or canine OS has been published, yet TLRs and their 
respective agonists constitute an attractive area of immunotherapy from a translational perspective, 
given their ability to be used across-species without substantial modification, which is often not 
the case with passive immunotherapies such as mAbs.  Therefore, we chose to employ a top-down, 
systematic approach to identify TLR agonist(s) that would maximize anti-tumor immunity while 
minimizing OS pro-inflammatory tumorigenesis, with the ultimate goal of identifying a TLR 
agonist with the potential to be employed within pet dogs with spontaneous OS. 
 This chapter elaborates on the preliminary studies that identified the TLR agonists 
Pam3CSK4 (TLR1/2), Poly(I:C) (TLR3), and CpG ODN 2395 (TLR9) as potential 
immunotherapeutics to employ within Chapter III, which utilizes a clinically-relevant murine 
model of metastatic OS.  We show that TLRs exhibit a dichotomous nature in regard to mRNA 
expression, that cellular viability is also variably influenced by different TLR agonists, and even 
classical inflammatory and pro-tumorigenic cytokine secretion differs depending on the agonist 
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investigated.  To round-out these studies, we integrated the evaluation of both murine and canine 
immune and OS cells to develop a better understanding of how different TLR agonists would 
function in a multi-species capacity.  Furthermore, our investigations suggested that out of our 3 
candidate TLR agonists, the TLR9 agonist CpG ODN 2395 may be least pro-tumorigenic in an 
OS setting while still promoting a meaningful anti-tumor immune response. 
 
Introduction 
 TLRs are a class of type I transmembrane proteins that function as pattern recognition 
receptors (PRRs), which recognize conserved pathogen-associated molecular patterns (PAMPs) 
from various bacteria, fungi, protozoa, parasites, and viruses.1,2  TLRs are classically recognized 
to be expressed by macrophages and dendritic cells, key players in the innate immune system, but 
TLRs can also be expressed by surface epithelium and mesenchymal tissue, along with B and T 
cells of the adaptive immune system.1,3-5 Numerous cancer histologies have also been shown to 
express TLRs, whether at normal tissue levels or in an aberrant nature.6-8 
 The subcellular location of TLRs varies, with TLR1, TLR2, TLR4, TLR5, TLR6, and 
TLR10 localized to the cytoplasmic membrane while TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, 
and TLR13 are found within the endosome.  To date, the human-expressed TLRs include TLR1-
10, while murine cells express TLR1-9 and TLR11-13.1,9 Various TLRs have also been shown to 
be expressed by canine cells.10-15 
 Subcellular localization is dictated by the specific class of pathogen recognized by each 
individual TLR.  For example, cytoplasmic membrane TLRs most often recognize bacterial-
associated PAMPS, while endosomal TLRs predominate with RNA (viral) or DNA 
(viral/bacterial) recognition; however, most TLRs are not restricted to recognizing only one class 
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of pathogen.  In addition to differing in their cognate ligands, signaling pathways for TLRs exhibit 
divergence, utilizing various TIR domain-containing adaptors such as MyD88, TRAM, TRIF, or 
TIRAP.  These various adaptors ultimately result in the activation of the MAPK pathway, along 
with additional downstream activation of specific transcription factors including NFκB or 
interferon regulatory factors (IRFs). Resultantly, TLR ligation and activation results in pro-
inflammatory cytokine and/or type I IFN secretion.  This innate immune response further shapes 
the adaptive immune system, resulting in system-wide pathogen defense.1,9,16,17 
 From an anti-tumor immunity standpoint, TLRs and their agonists are ideal candidates for 
the study and application of novel immunotherapeutics, given their conserved nature,18 ability to 
activate innate cell killing,19 and fine-tuning of the adaptive immune response,16 all of which are 
desirable traits in an immunotherapeutic.  However, TLRs have been shown to promote 
tumorigenesis through inflammation, yielding a so-called “double-edged sword” to this 
immunotherapeutic strategy, whereby pro-inflammatory tumorigenesis may override anti-tumor 
immunity.20  As the current evaluation of TLRs for the treatment of OS in both dogs and people is 
very limited, this “double-edge” theory led us to initially determine the expression and 
functionality amongst multiple TLRs and their respective agonists comparatively between innate 
immune and OS cells, in an effort to shift the balance toward anti-tumor immunity and away from 
pro-inflammatory tumorigenesis.  We hypothesized that there would be divergence between 
expression and functionality between immune and OS cells, allowing for the selection of 2-3 TLR 
agonists that could preferentially shift the balance away from tumorigenesis and towards anti-
tumor immunity. 
 Our findings support our hypothesis, showing that TLRs do exhibit some level of 
variability in expression between immune and OS cells, while agonism with various ligands can 
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either enhance or decrease cellular viability.  Based on this expression and functionality data, we 
choose to further investigate Pam3CSK4 (TLR1/2), Poly(I:C) (TLR3), and CpG ODN 2395 
(TLR9) based upon their promising differentials within these assays.  These 3 agonists were then 
subjected to measures of pro-inflammatory and pro-tumorigenic cytokine secretion, along with 
investigation of pro-tumorigenic protein upregulation.  Here we show all three agonists 
upregulated various pro-inflammatory cytokines that bolster anti-tumor immunity, but exhibited 
more discriminatory divergence in the production of certain pro-tumorigenic cytokines, such as 
IL-6, IL-8, and VEGF.   While none of these agonists appeared to strictly shift the balance solely 
towards tumorigenesis, CpG ODN 2395 (TLR9) was identified as having the best potential for 
initiating pro-inflammatory anti-tumor immunity with concurrent minimal upregulation of a pro-
tumorigenic environment in the context of OS. 
  
Materials and Methods 
Cell Lines 
 Murine immune cell lines D2SC/1, J774, and RAW and clonally-related21 osteosarcoma 
cell lines K7M2 and K12 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S) at 37ºC 
and 5% CO2 in a humidified incubator and passaged as needed.  Canine immune cell lines DH82, 






Toll-Like Receptors Agonists 
 TLR agonists for TLRs 2, 3, 4, 7, and 9 were purchased from InvivoGen (San Diego, CA) 
and reconstituted in endotoxin-free water.  A complete list of the TLR agonists investigated is 
provided in Table 2.1. 
 
MTS Assays for Initial TLR Agonist Screening 
 Immune and OS cells were plated at 5-10,000 cells/well and allowed to adhere overnight.  
Media was then replaced with new media containing various TLR agonists (Table 2.1) at 3-4 
different concentrations per agonist.  Concentrations investigated for each ligand were based upon 
TLR activation ranges provided by InvivoGen.  After 20 hours of treatment, media supernatants 
were removed, and cells were analyzed via colorimetric MTS measurement with the CellTiter 96 
AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) to quantify cellular 
viability in response to TLR agonist treatment. 
 
Enzyme-Linked Immunosorbent Assays 
 Commercially available enzyme-linked immunosorbent assays (ELISAs) were purchased 
for cytokine assessment.  Murine-specific IL-6, IL-12 p70, TNFα, and VEGF were measured with 
Quantikine ELISA (R&D Systems, Minneapolis, MN).  Murine-specific IFNα was measured with 
VeriKine ELISA (PBL Assay Science, Piscataway, NJ).  Murine-specific IL-8 was measured with 
Mouse IL-8 ELISA (MyBioSource, San Diego, CA).  Canine-specific IL-6, IL-8, and TNFα were 
measured with Quantikine ELISA and IL-12/IL-23 p40 was measured with DuoSet ELISA (R&D 
Systems).  Canine-specific IFNα was measured with Canine IFNα ELISA (MyBioSource). 
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 Murine and canine cell lines were plated in quadruplicate at a density of 10,000 cells/well 
in DMEM supplemented with 10% FBS and 1% P/S and allowed to adhere overnight.  The next 
day, the media was replaced with new media containing either Pam3CSK4, Poly(I:C), or CpG 
ODN 2395 at varying concentrations (0.3, 1, or 10 µg/mL for Pam3CSK4; 10, 30, or 100 µg/mL 
for Poly(I:C); 1, 25, or 50 µg/mL for CpG ODN 2395).  After a 20-hour incubation, the plates 
were centrifuged for 5 minutes to settle any floating cells, then media supernatants were collected 
and frozen back at -80ºC until ELISA analysis was performed.  After media removal, adherent 
cells were analyzed via MTS assay (Promega) for normalization of ELISA results. 
 
  Real-Time PCR (qPCR) 
Total RNA was extracted from cells harvested from confluent petri dishes using the 
RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions for animal 
cells.  Total RNA extraction was followed with DNase treatment using either an RNase-free DNase 
Set (Qiagen) or the TURBO DNA-free Kit (Invitrogen, Carlsbad, CA).  DNase-treated total RNA 
samples were purified via ethanol precipitation.  RNA was then quantified and assessed for purity 
with the NanoDrop 1000 or the NanoDrop One (Thermo Scientific, Waltham, MA).  RNA integrity 
was measured using the Agilent 2100 Bioanalyzer (Santa Clara, CA).  All RNA samples chosen 
for cDNA synthesis had an A260/280 ratio >1.8, A260/230 ratio <2.4, and RNA integrity number 
(RIN) >8. 
Following quantification and RIN analysis, 2 µg of RNA was reverse-transcribed to cDNA 
with the SuperScript or SuperScript III First Strand Synthesis System (Invitrogen) for murine and 
canine samples, respectively, using random hexamers.  No reverse transcriptase (-RT) controls 
were also prepared for each sample.  25 ng of the resultant cDNA was used in a 25 µL-PCR 
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reaction composed of 12.5 µL TaqMan Universal Master Mix II with UNG (Applied Biosystems, 
Foster City, CA), 6.25 µL water, and 1.25 µL TaqMan Gene Expression Assay (Applied 
Biosystems).  The TaqMan Gene Expression Assays consist of pre-mixed primers and the TaqMan 
MGB probe at a 20x concentration.  Murine and canine genes of interest (GOI) and corresponding 
assay numbers are listed in Tables 2.2 and 2.3, respectively. 
For each GOI, three biological replicates from each cell line were run in triplicate on an 
Applied Biosystems 7500 Real-Time PCR System.  No template controls were also utilized during 
each run to assess for genomic DNA contamination within the PCR mixture.  Negative RT controls 
were run in triplicate for each sample at least once with a primer/probe set that could detect 
genomic DNA, to ensure the efficacy of DNase treatment.  For canine TLR3, the amplification 
efficiency of the custom primer/probe set (AJWR2PO) was determined to be 96%, calculated from 
the slope of a standard curve generated from a 2-fold dilution series.  The run method for all 
reactions included 2 minutes at 50°C for UNG incubation, 10 minutes at 95°C for polymerase 
activation, followed by 40 cycles of denaturing at 95°C for 15 seconds and annealing/extending at 
60°C for 1 minute.  Normfinder, a free Excel add-in, was used to determine the most stable 
reference gene for each species.22  DCT was calculated for each biological replicate by the equation 
DCT = CT target - CT reference.  Based off Normfinder stability values, GAPDH was used for the 
reference gene in both species. 
 
Western Blot Analysis 
 K7M2, K12, and Abrams cell lines were grown to 80% confluence in petri dishes and 
treated with either Pam3CSK4, Poly(I:C), or CpG ODN 2395 for 20 hours, at the same 
concentrations utilized for ELISA cytokine measurement.  After 20 hours, cell pellets were 
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collected and protein was extracted using M-PER Mammalian Protein Extraction Reagent 
(Thermo Scientific).  Protein levels were determined with the Pierce BCA Protein Assay Kit 
(Thermo Scientific).  Based off protein measurements, 50 µg protein from each cell line and 
treatment concentration were resolved using 4-20% SDS-PAGE (Mini-PROTEAN TGX Pre-cast 
Gels, Bio-Rad, Hercules, CA) and transferred onto nitrocellulose or PVDF membranes.  
Membranes were blocked with 5% non-fat dry milk powder in tris-buffered saline/Tween 20 
(TBS-T) for 1 hour at room temperature, then incubated with primary antibody for 16 hours at 
4°C.  Primary antibodies for Bcl-2 (BD610538) were utilized at a dilution of 1:500 for murine 
cells and 1:1000 for canine cells.  XIAP (cs2042) and pAkt (cs9271) were utilized at a dilution of 
1:500 and 1:1000, respectively, for both species.  
 Primary antibody incubation was followed by three washes in TBS-T, then HRP-
conjugated secondary antibody was added for 1 hr at room temperature at 1:1000 in 5% milk + 
TBS-T.  Three additional washes in TBS-T were performed prior to imaging using an enhanced 
chemiluminescent (ECL) substrate (SuperSignal West Femto Maximum Sensitivity Substrate, 
Thermo Scientific) and the ChemiDoc XRS+ System (Bio-Rad).  Band volume analysis was 
performed using Image Lab software (Bio-Rad).   Bcl-2 and XIAP bands were normalized to b-
actin (ab6276, 1:5000 dilution).  pAkt bands were normalized to Akt (cs9272; 1:1000 dilution).  
Protein expression for each treatment concentration was determined and expressed as a percent 
qualitative change (±50%) relative to the untreated control. 
 
Statistical Analysis 
 Statistical analysis was performed with GraphPad Prism version 7.0a for Mac OS X 
(GraphPad Software, La Jolla, CA).  Significance was set at p < 0.05.  qPCR, MTS, and ELISA 
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data are expressed as the mean ± standard error of the mean (SEM).  Normality was assessed with 
the Shapiro-Wilk test.  One-way ANOVA with Tukey’s was used for parametric qPCR data and 
the Kruskal-Wallis test with Dunn’s was used for non-parametric qPCR data.  MTS assay data was 
assessed with 2-way ANOVA without matching and Dunnett’s.  Parametric ELISA data was 
analyzed with one-way ANOVA with Dunnett’s and non-parametric data with the Kruskal-Wallis 
test with Dunn’s.  For all data, *p < 0.05, **p < 0.01, and ***p < 0.001.   
 
Results 
TLRs Exhibit Differential Expression in Immune and OS Cells 
 While TLR expression has been extensively evaluated in numerous cancer histologies, 
minimal investigation of TLR expression in osteosarcoma has been published to date.23-27 
Therefore, we sought to determine if differential expression between immortalized immune and 
OS cells were distinguishable by qPCR, as dichotomous expression between the immune system 
and OS may help guide a rational therapeutic choice of TLR agonist.  To this extent, we performed 
baseline TLR mRNA expression levels using Taqman qPCR on immune and OS cells of murine 
and canine origin (Figures 2.1 and 2.2).  Murine immune and OS cells exhibited no difference in 
DCT for TLR2, TLR4, and TLR7 (Figure 2.1a, d, e).  However, when analyzed as a group, murine 
OS cells (K7M2 and K12) had lower expression of TLR2 (characterized by increased DCT) when 
compared to immune cells (Figure 2.1b).  TLR3 expression was not different between most 
murine immune and OS cell comparisons, except for RAW and K7M2, where RAW (average DCT 
=13) had decreased expression of TLR3 comparatively to K7M2 (average DCT =7) (Figure 2.1c).  
Both K7M2 and K12 also failed to have measurable CT values for TLR9, while the immune cells 
had abundant expression of TLR9 with low DCT (Figure 2.1f).   
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 For canine immune cells, the Nike cell line did have not measurable CT values for any GOI 
except RPS18, a potential reference gene, and a single Nike biological replicate had a high CT of 
37 for TLR9 (data not shown).  PCR results from 030-D are also not shown, as although GAPDH 
was the most stable reference gene overall, 030-D had on average a 23-fold increase in expression 
of GAPDH relative to the other cell lines, which skewed group-wise comparisons.  TLR CT values 
for 030-D, however, were often within 1-2 cycles of DH82 values.  Decreased expression of TLR2 
and TLR4 was observed for canine OS cells in comparison to the immune cell line DH82 for 1-2 
of the three canine OS cell lines screened (Abrams and/or K003) (Figure 2.2a, c).  Trends towards 
decreased expression of TLR3 and TLR7 were also noted for the OS cell lines, but were not 
statistically significant (Figure 2.2b, d).  TLR9 expression did not differ between canine immune 
and OS cells (Figure 2.2e).  From these results, we concluded that neither murine nor canine OS 
cells consistently express aberrantly high levels of TLRs compared to immune cells of the same 
species, although differential expression was occasionally observed between immune and OS cells.  
This differential expression was most apparent with TLR2 and TLR9, which were flagged as 
potential targets. This was based off the consistent increase in TLR2 DCT for OS cells across both 
species (equating to less expression of TLR2 comparatively to the immune cells), and the lack of 
measurable TLR9 expression in murine OS in combination with stable TLR9 expression for canine 
OS. 
 
TLR Agonists Variably Influence Cellular Proliferation 
 qPCR results identified TLR2 and TLR9 as promising targets for potential immunotherapy 
in OS; however, mRNA expression does not always correlate to protein expression and also does 
not indicate the level of receptor functionality.  Therefore, we sought to assess the influence of 
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TLR agonists on OS cellular proliferation and metabolism, in order to identify potential agonists 
that may not be directly stimulatory to OS, but could still have the potential to exert positive 
immunobiological effects.  
To assess this, we screened multiple TLR agonists in vitro (Table 2.1) in both murine and 
canine immune and OS cells utilizing MTS optical density (OD) as indicative of changes in cellular 
viability after 20 hours of TLR agonist incubation (Figures 2.3 and 2.4).  Results were highly 
variable between immune and OS cells of both species.  Murine immune cells D2SC/1 and RAW 
responded most robustly to CpG ODN 2395 (TLR9) incubation, with significantly increased OD 
levels at all 3 concentrations (1, 25, and 50 µg/mL) investigated compared to untreated controls 
(Figure 2.3h).  RAW immune cells also expressed higher OD with LTA (TLR2) and Imiquimod 
(TLR7) treatment (Figure 2.3b, f).  All other TLR agonists exhibited either stable or decreased 
OD for murine immune cells (Figure 2.3a, c-e, g).  Comparatively, CpG ODN 2395 at 50 µg/mL 
was the only TLR agonist to elevate OD in the canine immune cell line DH82 (Figure 2.4h).  
These findings suggest that the TLR9 agonist CpG ODN 2395 has the most widespread ability to 
influence cellular proliferation in immune cells of multiple origins. 
 OS cells also exhibited variable responses secondary to TLR agonism.  For CpG ODN 
2395, no change in OD was observed for either murine or canine OS (Figures 2.3h and 2.4h).  
Pam3CSK4 (TLR1/2) caused significant decreases in OD for both murine and OS cell lines at the 
highest concentration of 10 µg/mL (Figure 2.3a and 2.4a).  Poly(A:U)  and Poly(I:C), both TLR3 
ligands, caused variable, often dose-dependent decreases for murine OS (Figure 2.3c, d).  This 
effect was also sustained for Poly(A:U) in canine OS (Figure 2.4c), but was not observed in canine 
OS with Poly(I:C) (Figure 2.4d).  Imiquimod decreased OD in both murine OS lines (Figure 
2.3f), but remained stable overall amongst canine OS (Figure 2.4f).  LTA, LPS (TLR4), and E. 
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coli ssDNA (TLR9) agonism resulted in either elevated or stable OD amongst the majority of 
murine and canine OS cell lines (Figures 2.3b, e, g, and 2.4b, e, g).  When evaluating which 
agonists had a positive viability or proliferative effect on immune cells while concurrently 
exhibiting a predominantly stable or inhibitory effect on OS cells across both species, the findings 
identified Pam3CSK4 (TLR1/2), Poly(A:U)/Poly(I:C) (TLR3), and CpG ODN 2395 (TLR9) as 
possible candidates for further evaluation. 
 Based upon collective MTS assay and qPCR results, we determined that Pam3CSK4 
(TLR1/2), Poly(I:C) (TLR3), and CpG ODN (TLR9) were all reasonable candidates for further 
evaluation as potential therapeutics for metastatic OS.  While Poly(I:C) did not exhibit as profound 
inhibitory effects as Poly(A:U) within the MTS assay, it was chosen over Poly(A:U) due to its 
stronger immunogenicity. 
 
TLR1/2, 3, and 9 Agonists Induce Robust TNFα Secretion in Immune Cells 
 To examine the potential immunobiologic activity of our 3 selected TLR agonists, we 
quantified secretion of several important immunological cytokines by our murine (D2SC/1, J774, 
RAW) and canine (DH82, Nike, 030-D) immune cell lines.  IL-12, IFNα, and TNFα were 
measured via species-specific ELISA in response to a 20 hour incubation with the TLR agonists 
Pam3CSK4 (TLR1/2), Poly(I:C) (TLR3), and CpG ODN 2395 (TLR9).  Murine immune cells 
exhibited robust secretion of TNFα in response to all 3 agonists (Figure 2.5).  This secretion was 
consistently dose-dependent for all lines, except RAW, which in response to Pam3CSK4 and CpG 
ODN 2395 exhibited maximal secretion levels at the lowest concentration levels evaluated (0.3 
µg/mL and 1 µg/mL, respectively).  DH82 secreted elevated levels of TNFα in response to 
Pam3CSK4 and Poly(I:C) at all three concentrations tested, these levels were dose-dependent for 
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Poly(I:C) but not for Pam3SK4.  Measurable TNFα levels, however, were only detected at the 
highest concentration of CpG ODN 2395 (50 µg/mL) for DH82.  No statistical change in 
measurable TNFα was observed for 030-D with either Pam3CSK4 or CpG ODN 2395, but 
significant increases were noted with Poly(I:C) treatment (Figure 2.6).  Nike failed to secrete 
TNFα under normal conditions or in the presence of any agonist (data not shown). 
 IL-12 secretion was not detectable in any of the canine immune cells, regardless of 
treatment, and was not detectable in response to Pam3CSK4 within the murine immune cells (data 
not shown).  IL-12 was only elevated in response to Poly(I:C) treatment at high doses within the 
RAW murine cell line, whereas CpG ODN 2395 decreased secretion.  For D2SC/1 and J774, IL-
12 secretion was either stable or decreased with Poly(I:C) and CpG ODN 2395 (Figure 2.7).  IFNα 
was also not detected in response to Pam3CSK4 and CpG ODN 2395 in the murine immune cells 
(data not shown), but was increased in J774 and RAW cells with Poly(I:C).  D2SC/1 did not secrete 
IFNα (Figure 2.8).  Elevations in IFNα in the canine cell lines was minimal in response to all three 
TLR agonists (Figure 2.9). 
 
CpG ODN 2395 Exerts Minimal Pro-Tumorigenic Activity In Vitro 
 In addition to evaluating potential immunobiologic activity of our 3 selected TLR agonists, 
it was equally important to evaluate the pro-tumorigenic activity of these agonists within OS cells, 
the intended therapeutic target.  To this extent, we chose to evaluate the secretion of several 
cytokines (IL-6, IL-8, and VEGF) and the expression levels of proteins (Bcl-2, XIAP, pAkt) 
central to OS tumorigenesis,28 in response to a 20 hour incubation with the selected agonists. 
 All 5 OS cell lines previously evaluated (murine OS cell lines K7M2 and K12; canine OS 
cell lines Abrams, HMPOS, and K003) were included in the evaluation of pro-tumorigenic 
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cytokine secretion in response to TLR agonism.  The murine OS cells, K7M2 (Figure 2.10a) and 
K12 (Figure 2.10b), responded similarly to Pam3CSK4 treatment with stable production of IL-8 
and increased production of VEGF, but had variable production of IL-6 (increased for K7M2 and 
decreased to steady for K12).  Poly(I:C) treatment also stimulated production of IL-6 and IL-8 in 
both murine OS lines, but was inhibitory for K7M2 VEGF secretion at elevated concentrations 
and stimulatory for K12.  CpG ODN 2395 therapy resulted in either stable (IL-6, IL-8) or reduced 
(VEGF) production in K7M2.  K12 cells responded with initial peaks in secretion for IL-6 and 
VEGF, followed by a return to basal secretion levels at doses of 25 and 50 µg/mL.  For IL-8, 
however, K12 cells exhibited increased secretion amongst all treatment levels but the absolute 
increase in IL-8 concentrations remained minimal (less than 30 pg/mL). 
 Pam3CSK4 also consistently induced elevated production of all 3 cytokines amongst the 
Abrams (Figure 2.11a), HMPOS (Figure 2.11b), and K003 (Figure 2.11c) canine OS cell lines.  
Similarly, Poly(I:C) treatment induced secretion of IL-6 and IL-8 amongst the canine OS cells 
except for K003, which had stable secretion of IL-6 regardless of Poly(I:C) concentration.  VEGF 
secretion elevated in response to low-levels of Poly(I:C) in Abrams, but remained stable to 
decreased in HMPOS and K003.  CpG ODN 2395 did not increase IL-6, IL-8, or VEGF levels, 
with the exception of IL-6 in HMPOS, which went from undetectable to detectable with CpG ODN 
2395 treatment.  This conversion to detectable secretion was not statistically significant. 
 For pro-tumorigenic protein expression (Figure 2.12), data was compared qualitatively to 
untreated controls for K7M2, K12, and Abrams.  The K12 murine OS cell line was the only cell 
line to have an elevation >50% of baseline expression levels (74% increase in Bcl-2 in response 
to 10 µg/mL of Pam3CSK4).  The majority of changes, however, were within ±50% of untreated 
baseline expression levels and were not considered significant.  Few scenarios resulted in a 
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decrease >50% of baseline.  This included a 59% reduction in pAkt for Abrams treated with 
Pam3CSK4 (1 and 10 µg/mL), a 60% (100 µg/mL) and 62% (30 µg/mL) reduction in XIAP for 
K7M2 and K12, respectively, with Poly(I:C) treatment, and a 75% reduction in pAkt for K7M2 
with CpG ODN 2395.  The K12 cell line also demonstrated a 74% and 69% reduction in pAkt 
following high-doses of CpG ODN 2395 (25 and 50 µg/mL, respectively).   
 
Discussion 
 While the findings from this chapter were informative and support our hypothesis of 
divergence between expression and functionality amongst various TLRs and their respected 
agonists, overall directionality of the data (both between and within species) was not uniform.  
This lack of uniformity was not unexpected, and when we concentrated on the most salient features 
of each methodology employed, important trends do appear. 
 In the murine cell lines evaluated, we were unable to produce TLR9 amplicons with qPCR 
for both the K7M2 (metastatic) and K12 (non-metastatic) cell lines, while the immune cell lines 
had high levels of mRNA expression.  This could be due to our Taqman assay not having adequate 
TLR9 transcript coverage, but unfortunately, no alternative Taqman assays for murine TLR9 are 
currently available.  However, this finding does raise the possibility that TLR9 protein expression 
in the murine OS cell lines is minimal, which might negate pro-tumorigenic activities of TLR9 
agonism in vivo.  This, while only theoretical, would be highly beneficial from a therapeutic 
standpoint.  Although the canine OS cell lines did have measurable TLR9 mRNA levels, their 
expression levels were not different from the immune cells, suggesting TLR9 levels in canine OS 
are not aberrantly upregulated. 
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 Cytokine secretion by the murine immune cell lines was not discriminatory between TLR2, 
TLR3, and TLR9, as all three agonists amplified TNFα, and exhibited only random and marginal 
effects on other important immune cytokines (IL-12 and IFNα).  When also evaluating pro-
tumorigenic cytokine secretion by K7M2, CpG ODN 2395 appeared most favorable from a strict 
tumorigenesis angle, but Poly(I:C) also had minimal pro-tumorigenic cytokine effects and was 
more pan-immunostimulatory than CpG ODN 2395.  Interestingly, when evaluating pro-
tumorigenic protein expression, Poly(I:C) elevated pAkt in K7M2, whereas CpG ODN 2395 
decreased pAkt.  When including murine mRNA expression levels, the culmination of these results 
are most favorable for CpG ODN 2395, although Poly(I:C) appears more immunostimulatory.    
 Canine qPCR was unable to provide clear differences between TLR mRNA between 
immune and OS cell lines, unlike what we observed in our murine studies.  While this does indicate 
TLR mRNA are not upregulated in canine OS, it does not provide a clear guide for agonist 
selection.  Similar to the murine results, however, TNFα is the major immune cytokine stimulated, 
but IFNα levels rarely responded to TLR agonism.  IL-12 levels were also unchanged in response 
to TLR agonism.  These negative results (IFNα and IL-12) may be dose-dependent or time-
dependent, as we only investigated a few concentrations of agonist and utilized a single standard 
incubation time.  The Nike and 030-D canine immune cell lines are also poorly characterized and 
evaluation of canine peripheral blood mononuclear cells (PBMCs) may better represent the 
immune response to TLR agonism in dogs.  Canine OS cell lines, however, had significant 
increases in both IL-6 and IL-8 for Pam3CSK4 and Poly(I:C), with less effects on VEGF, while 
CpG ODN 2395 had minimal pro-tumorigenic activity.  This lack of pro-tumorigenic activity also 
shifted favoritism towards TLR9 agonism within the canine lines. 
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 Overall, this in vitro data does support evaluating all 3 agonists (Pam3CSK4, Poly(I:C), 
and CpG ODN 2395) in a syngeneic murine model of OS, as there is no clear winner from the 
expression and functionality studies investigated.  While this data suggests CpG ODN 2395 may 
be least pro-tumorigenic, we are fully aware that these experiments do not adequately capture the 
many interactions that occur within a living organism undergoing cancer therapy.  Thus, 
application of these agonists within a murine model of OS is necessary for full appreciation of 














FIGURES AND TABLES 
 
TLR Agonist Origin Ligand for InvivoGen# 
Pam3CSK4 Synthetic triacylated bacterial lipoprotein TLR1/2 tlrl-pms 
LTA-SA Purified Lipotechoic acid from S. aureus TLR2 tlrl-pslta 
Poly(A:U) Synthetic dsRNA TLR3 tlrl-pau 
Poly(I:C) HMW High molecular weight synthetic dsRNA TLR3 tlrl-pic 
LPS-B5 Ultrapure LPS from E. coli 055:B5; 
enzymatically treated to remove lipopeptides 
TLR4 tlrl-pb5lps 
Imiquimod (R837) Synthetic imidazoquinoline amine TLR7 tlrl-imq 
E. coli ssDNA   
plus LyoVec 
Lyophilized E. coli K12 ssDNA combined with 
LyoVec lipid-based transfection reagent 
TLR9 tlrl-ssec 
CpG ODN 2395 Synthetic Class C CpG oligonucleotide; 
human/murine specific 
TLR9 tlrl-2395 
   Table 2.1: Summary of TLR agonists investigated for potential OS immunotherapy.  
   The TLR agonists listed were initially screened for stimulatory activity in immune and OS  


















Gene Expression Assay 
Gene Name Amplicon Length (bp) 
Mm00442346_m1 TLR2 69 
Mm01207404_m1 TLR3 121 
Mm00445273_m1 TLR4 87 
Mm00446590_m1 TLR7 125 
Mm00446193_m1 TLR9 60 
Mm99999915_g1* GAPDH 107 
Mm01197698_m1 GUSB 71 
Mm01143545_m1 HMBS 81 
Mm02619580_g1* ACTB 143 
Mm00437762_m1 B2M  77  
   Table 2.2: Murine genes investigated and the primer/probe sets utilized for RT-PCR. 
























Gene Expression Assay 
Gene Name Amplicon Length (bp) 
Cf03034088_s1** TLR2 110 
AJWR2PO*** TLR3 62 
Cf02622203_g1* TLR4 120 
Cf02710573_s1** TLR7 124 
Cf02622347_g1* TLR9 87 
Cf02717353_g1* TLR9 136 







Cf02681523_g1 RPS18 160 
  Table 2.3: Canine genes investigated and the primer/probe sets utilized for RT-PCR.  
  *Designates an assay that may detect genomic DNA, **designates an assay that will  

















Figure 2.1:  Normalized qPCR mRNA levels for TLRs 2, 3, 4, 7, and 9 in murine immune 
and OS cell lines (A-F).  Immune cells include D2SC/1, J774, and RAW.  OS cells include 
K7M2 and K12.  Murine OS cells as a group exhibit less expression of TLR2 compared to 
immune cells (B).  No amplification for TLR9 (F) was observed for either OS line; therefore, 
the CT level was arbitrarily set at 41 for graphical purposes.  K7M2 and K12 are also 
statistically different from all immune cell lines for TLR9.  One-way ANOVA.  *p<0.05 and 





















































































































































































































































































































Figure 2.2:  Normalized qPCR mRNA levels for TLRs 2, 3, 4, 7, and 9 in canine 
immune and OS cell lines (A-E).  Immune cells are represented by DH82.  OS cells include 
Abrams, HMPOS, and K003.  TLR2 (A) and TLR4 (B) have lower expression in Abrams 
and/or K003 OS cell lines compared to DH82.  Expression of TLR3 (C), TLR7 (D), and 
TLR9 (E) are not significantly different between canine immune and OS cells.  One-way 
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Figure 2.3:  Cellular viability as measured by MTS assay in response to various 
TLR agonists for murine immune and OS cell lines.  
Murine immune cells represented by D2SC/1, J774, and RAW.  Murine OS cells 
represented by K7M2 and K12 (as viewed from top to bottom of each graph).  Note how 
Pam3CSK4 (A), Poly(A:U) (C), Poly(I:C) (D), and Imiquimod (F) treatments cause 
decreased cellular viability within the OS cell lines.  CpG ODN 2395 (H) treatment does 
not affect cellular viability within the OS cells.  Two-way ANOVA.  *p<0.05, **p<0.01, 
and ***p<0.001   
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Figure 2.4:  Cellular viability as measured by MTS assay in response to various TLR 
agonists for canine immune and OS cell lines.  
Canine immune cells represented by DH82.  Canine OS cells represented by Abrams, 
HMPOS, and K003 (as viewed from top to bottom of each graph).  Note how Pam3CSK4 (A) 
and Poly(A:U) (C) treatments cause decreased cellular viability within the OS cell lines.  CpG 
ODN 2395 (H) treatment does not affect cellular viability within the OS cells.  Two-way 
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Figure 2.5:  Normalized TNFα secretion in response to Pam3CSK4, Poly(I:C), or CpG 
ODN 2395 treatment in murine immune cells.  
All three murine immune cell lines investigated (D2SC/1, J774, and RAW) exhibit robust 
secretion of TNFα in response to TLR agonist treatment.  This secretion is often dose-
dependent.  One-way ANOVA.  **p<0.01 and ***p<0.001   
 






































































































































































































































































































































































































Figure 2.6:  Normalized TNFα secretion in response to Pam3CSK4, Poly(I:C), or 
CpG ODN 2395 treatment in canine immune cells. 
DH82 responds to all three agonists with increases in TNFα secretion, whereas 030-D only 
increases secretion in response to Poly(I:C).  The Nike cell line did not secrete measurable 













































































































D2SC/1 RAW J774 
Figure 2.7:  Normalized IL-12 secretion in response to Pam3CSK4, Poly(I:C), or CpG 
ODN 2395 treatment in murine immune cells.  
Poly(I:C) was the only agonist to successfully increase IL-12 secretion, which was limited 
to the RAW cell line.  No measurable secretion of IL-12 was observed with Pam3CSK4 
treatment (data not shown).  One-way ANOVA.  *p<0.05, **p<0.01, and ***p<0.001   
 




















































































































































D2SC/1 RAW J774 
Figure 2.8:  Normalized IFNα secretion in response to Pam3CSK4, Poly(I:C), or CpG 
ODN 2395 treatment in murine immune cells.  
Poly(I:C) was the only agonist to successfully increase IFNα secretion and was limited to 
J774 and RAW cells.  No measurable secretion of IFNα was observed with Pam3CSK4 or 
CpG ODN 2395 treatment (data not shown).  One-way ANOVA.  *p<0.05, **p<0.01, and 

































































































Figure 2.9:  Normalized IFNα secretion in response to Pam3CSK4, Poly(I:C), or CpG 
ODN 2395 treatment in canine immune cells.  
All three agonists induce minimal to no significant increases in IFNα amongst canine 
immune cell lines.  One-way ANOVA.  *p<0.05 and **p<0.01  
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Figure 2.10:  Normalized pro-tumorigenic cytokine secretion in response to Pam3CSK4, 
Poly(I:C), and CpG ODN 2395 in murine OS cells. 
K7M2 (A) and K12 (B) both exhibit variable responses in IL-6, IL-8, and VEGF secretion.  
However, CpG ODN 2395 has the most consistent response across both cell lines, in regard to 










Figure 2.11A-B:  Normalized pro-tumorigenic cytokine secretion in response to 
Pam3CSK4, Poly(I:C), and CpG ODN 2395 in canine Abrams and HMPOS OS cells. 
Abrams (A) and HMPOS (B) exhibit variable responses in IL-6, IL-8, and VEGF secretion.  
Similar to the murine OS cell lines, CpG ODN 2395 has the most consistent response across 
both cell lines, in regard to minimizing overall upregulation of each cytokine.  One-way 
ANOVA.  *p<0.05, **p<0.01, and ***p<0.001 
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Figure 2.11C (cont.):  Normalized pro-tumorigenic cytokine secretion in response to 
Pam3CSK4, Poly(I:C), and CpG ODN 2395 in canine K003 OS cells. 
K003 (C) also exhibits variable responses in IL-6, IL-8, and VEGF secretion.  While Poly(I:C) 
does not result in increased IL-6 or VEGF secretion, CpG ODN 2395 does not increase 
secretion of any pro-tumorigenic cytokine investigated (IL-6, IL-8, and VEGF).  These findings 
corroborate what is observed in Abrams and HMPOS, along with the murine OS cell lines 
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INVESTIGATING THE PRO- AND ANTI-TUMORIGENIC ACTIVITY OF SELECT 
TOLL-LIKE RECEPTOR AGONISTS IN A MURINE MODEL OF OSTEOSARCOMA 
 
Abstract 
 The K7M2 syngeneic Balb/c model of metastatic OS is a popular model for the pre-clinical 
evaluation of new OS therapeutics and for studying the mechanisms underlying OS pathogenesis.  
This model has several variations, including an orthotopic and tail vein model, with the tail vein 
model producing fast but consistent replication of experimental OS pulmonary metastasis.  
Although mouse models of disease do not always accurately recapitulate or predict outcomes in 
large animal models of disease, it was prudent to evaluate and characterize the activity of these 
potential therapeutics in a small animal model prior to employing them within a clinical setting.  
Based upon our findings in Chapter II, we choose to evaluate Pam3CSK4, Poly(I:C), and CpG 
ODN 2395 in this clinically-relevant murine model of OS to further delineate their 
immunotherapeutic potential before use in dogs with spontaneous OS.   
 Our findings indicate Poly(I:C) and CpG ODN 2395 both inhibit the development of 
pulmonary metastasis in this model, while Pam3CSK4 appears to have tumor-promoting 
capabilities.  However, the effect of Poly(I:C) is apparently short-lived while CpG ODN 2395 has 
marked long-term positive outcomes, including significantly increased survival.  We also show 
CpG ODN 2395 promotes an increase in Th1 and cytotoxic T cells, but does not increase antigen-
specific cytotoxicity towards K7M2 nor does its therapeutic effect appear to be due to macrophage-
associated killing.  Additionally, we uncover the ability of CpG ODN 2395 to inhibit pulmonary 
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metastasis in a treatment/tumor emboli scheme closely mimicking the clinical course of OS 
therapy and disease in dogs. 
 
Introduction 
 The K7M2 OS cell line is derived from a spontaneous Balb/c OS.  It was created through 
intraosseous injection of the parent cell line K7 with reimplantation of subsequent K7 lung 
metastases into a parosteal tibial muscle flap.  This procedure was repeated until the K7M2 cell 
line was developed.  The K7M2 model can be used in 2 fashions: 1) as a syngeneic orthotopic 
model with eventual spontaneous metastasis or 2) tail vein injection for accelerated creation of 
experimental pulmonary metastases.  With the tail vein injection method, death from pulmonary 
metastases is 100% with a median survival time (MST) of 17 days, indicating its aggressive course 
but also allowing for the efficient study of OS metastasis in a syngeneic model.1,2  The K7M2 cell 
line also expresses some classical proteins of bone, such as osteopontin and osteocalcin, but lacks 
expression of alkaline phosphatase.1,3 
 Using the K7M2 tail vein injection model, we sought to evaluate whether our 3 selected 
TLR agonists from Chapter II (Pam3CSK4, Poly(I:C), and CpG ODN 2395) would be effective 
in reducing pulmonary metastasis and increasing survival time.  We also studied how these TLR 
agonists shape the immunophenotype of lymphocytes within OS-bearing mice and if TLR agonism 
increased specific cell-mediated cytotoxicity against K7M2.  We hypothesized that TLR agonism 
in this model would produce variable results, e.g. some agonists may promote a pro-tumorigenic 
phenotype while others may promote an anti-tumorigenic phenotype.  The results from this chapter 
indicate OS pulmonary metastasis in the K7M2 tail vein injection model can be inhibited by CpG 
ODN 2395, that CpG ODN 2395 induces increased numbers of anti-tumor lymphocyte 
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subpopulations in comparison to Pam3CSK4 and Poly(I:C), but that this reduction in lung tumor 
metastasis is likely not due to increases in antigen-specific cell-mediated cytotoxicity.  We also 
show that while CpG ODN 2395 induces phagocytosis in murine immune cells, macrophages do 
not appear to be the single critical component in the reduction of metastasis mediated by CpG 
ODN 2395 therapy.  CpG ODN 2395 also appears to have a narrow window of efficacy in the 
prevention of lung metastasis development, which requires further evaluation in future studies, but 
based off the significant increases in survival time that it can produce in this murine OS model, it 
is still an attractive therapy for use in dogs with spontaneous OS. 
 
Material and Methods 
Cell Lines 
 The murine OS cell line K7M2, murine immune cell lines J774 and RAW, and the canine 
immune cell lines DH82 and Nike were cultured in DMEM supplemented with 10% FBS and 1% 
P/S at 37ºC and 5% CO2 in a humidified incubator.  Prior to expansion of the K7M2 cell line for 
in vivo experiments, representative cell culture media aliquots were confirmed negative for 




Six- to eight-week-old female Balb/c mice were purchased from Charles River 
Laboratories (Wilmington, MA).  All mice were housed within the University of Illinois Division 
of Animal Resources facilities.  All studies were approved by the University of Illinois Institutional 
Animal Care and Use Committee (IACUC). 
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Prophylactic Toll-Like Receptor Agonist Treatment 
 Mice were injected subcutaneously (SQ) over the scruff of the neck weekly for four weeks 
with either Pam3CSK4 (10 µg/mouse), Poly(I:C) (100 µg/mouse), or CpG ODN (50 µg/mouse) 
in Hank’s Balanced Salt Solution (HBSS).  A subset of mice were injected with a tumor cell lysate 
consisting of 1x106 mycoplasma-negative K7M2 cells in addition to their respective TLR agonist 
treatment.  The tumor cell lysate was prepared by subjecting tumor cells to 8-10, -80°C freeze/thaw 
cycles followed by confirmation of <5% cell viability by trypan blue exclusion.  Total injection 
volume per mouse was 250 µL, regardless of treatment type (TLR agonist only vs. TLR agonist 
plus tumor cell lysate).  Sham controls were injected with an equal volume of HBSS.  Three days 
after the 4th TLR agonist treatment, mice were injected with 1x106 mycoplasma-negative K7M2 
in 200 µL HBSS via tail vein (day 0). Two, three, or four additional SQ TLR injections (+/- K7M2 
tumor cell lysate) were continued on a weekly basis.  Mice were then followed for survival time 
or sacrificed at day 14, day 21, or day 28 for assessment of lung tumor burden, collection of serum 
for cytokine assessment, and collection of spleens for flow cytometry. 
  
Flow Cytometry 
 Spleens were harvested from mice under the prophylactic TLR agonist treatment scheme 
(without concurrent tumor cell lysate treatment) at day 14 or day 28 post-K7M2 tail vein injection.  
Spleen weights were obtained, then spleens were homogenized between the frosted edges of two 
glass slides and mononuclear cells collected via gradient centrifugation using Histopaque 1.083 
(Sigma-Aldrich, St. Louis, MO) according to manufacturer’s instructions.  Total mononuclear cell 
counts were determined via hemocytometer chamber counts for each sample. 
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 Flow cytometry was performed on BD Accuri C6 or BD LSR II flow cytometry analyzers 
(BD Biosciences, San Jose, CA) using triple-stained samples to assess the following lymphocyte 
subpopulations:  cytotoxic T lymphocytes (CTL), Th1-polarized lymphocytes (Th1), T regulatory 
lymphocytes (Treg), and natural killer cells (NK).  Antibody-fluorochrome conjugates for each 
lymphocyte population are listed in Table 3.1.  Fluorescence Minus One (FMO), compensation, 
and isotype controls were run concurrently.  All antibodies and flow reagents were manufactured 
by eBioscience (Thermo Scientific). 
 Briefly, washed splenocytes were resuspended in chilled Flow Cytometry Staining Buffer 
with Fc Block (anti-mouse CD16/32; 0.5 µg/106 cells) and incubated for 15 minutes at 4ºC.  
Following blocking, splenocytes were washed in chilled flow buffer and then split into separate 
samples for triple-staining of lymphocyte subpopulations (Table 3.1).  Staining for each antibody-
fluorochrome conjugate was performed at ≤1.0 µg/106 cells.  Samples were incubated in the dark 
for 30 minutes, then washed 1x in chilled flow buffer followed by resuspension in chilled 
Fixation/Permeabilization Buffer.  Samples were then stored overnight in the dark at 4ºC.  The 
following morning, all samples were resuspended in chilled Permeabilization Buffer and samples 
for Treg analysis were incubated with anti-mouse FoxP3-APC antibody for 30 minutes in the dark 
at 4ºC.  Following washing of Treg samples, all samples were pelleted for removal of 
Permabilization Buffer supernatants and resuspended in 100 µL chilled flow buffer for subsequent 
analysis. 
 
Ex vivo cytotoxicity assays 
 Splenocytes were harvested from mice under the prophylactic TLR agonist treatment 
scheme using aseptic technique.  Splenocytes were collected using gentle dissociation from the 
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capsule using curved hemostats and mononuclear cells were collected using Histopaque 1.083.  
Total mononuclear cell counts were determined via hemocytometer chamber counts for each 
sample. 
Lymphocytes were plated over mitomycin c-treated K7M2 cells in 24 well plates at a 
lymphocyte density of 5x106/mL at a 2:1 ratio with mitomycin-c treated naïve splenocytes in the 
presence of rmIL-2 (0.25 ng/mL) in complete T cell media.  After 7 days of culture, the 
lymphocytes were assessed for cytotoxicity against the K7M2 and Balb/3T3 fibroblast cell lines 
using the LDH-based CytoTox 96 Non-Radioactive Assay kit (Promega).  Percent cytotoxicity 
was calculated using the equation: (experimental – effector spontaneous – target 
spontaneous)/(target maximum – target spontaneous) *100. 
 
Accelerated CpG ODN Treatment 
 Mice were injected with 1x106 K7M2 in 200 µL HBSS via tail vein.  Following tail vein 
injection mice were treated with CpG ODN on either day 0 (same day as K7M2 injection, typically 
within 2-4 hours after injection) or day 3, 5, or 7 post-tail vein injection.  CpG ODN was 
administered at 50 µg/mouse in 250 µL HBSS given SQ over the scruff of the neck.  Sham controls 
were injected with equal volumes of HBSS.  Mice were followed for survival or sacrificed at day 
21 for assessment of lung tumor burden and collection of serum for cytokine assessment.  Mice 
were given weekly CpG ODN injections on a continuous basis up until the point of sacrifice or 






Liposomal Clodronate for Macrophage Depletion 
 Liposomal clodronate (Clodrosome) was purchased from Encapsula NanoSciences 
(Brentwood, TN) for macrophage depletion.  To assess the efficacy of depletion in vivo, 
preliminary studies were performed where mice were treated either intraperitoneally (IP) or 
intranasally (IN) with clodronate over a 10-day period, following which mice were sacrificed for 
quantitative macrophage assessment.  Quantitative macrophage assessment included collection of 
spleens for macrophage immunohistochemistry (IHC) and bronchoalveolar lavage (BAL) 
collection for lung macrophage enumeration.  Subsets of mice within the accelerated CpG ODN 
treatment schemes were also treated with clodronate, to investigate the importance of macrophages 
in CpG ODN’s mechanism of action (MOA). 
 For mice receiving IP clodronate, a 2 mg loading dose was given initially, followed by 0.5 
mg doses every 3 days thereafter.  Mice receiving IN treatment were administered 0.3 mg 
clodronate via the nares weekly.  Mice receiving K7M2 tail vein injection and concurrent CpG 
ODN treatment were initially pre-treated with clodronate (IP or IN) for a 10-day period before 
tumor injection and TLR agonist administration commenced.  Clodronate treatments were 
continued as described above for preliminary depletion studies and CpG ODN was administered 
weekly until day 21 when mice were sacrificed for tumor burden assessment. 
  
Bronchoalveolar Lavage Analysis 
 BALs were processed by standard procedures at the University of Illinois Veterinary 
Diagnostic Laboratory, to obtain an automated total white blood cell count (cells/µL) and a 
differential cell count via cytology.  Differential counts (%) were performed by a board-certified 
clinical pathologist who was unaware of the study purpose.  Absolute BAL macrophages (cells/µL) 
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per mouse were calculated using BAL total white blood cell count (cells/µL) multiplied by percent 
macrophages. 
 
Lung Tumor Burden Measurement 
 Immediately following CO2 euthanasia, lungs were infused with 1-2 mL of India ink until 
fully inflated, then placed in Fekete’s solution for bleaching of tumor metastases and fixation.  
After 24-48 hours of fixation in Fekete’s solution, samples were stored in 70% ethanol until further 
processing.  Following fixation, single sections from each lung lobe were processed and embedded 
into paraffin blocks using standard protocols at the University of Illinois Veterinary Diagnostic 
Laboratory.  Five-micron tissue sections were cut in at two levels separated by 50 microns, placed 
onto glass slides, and stained routinely with hematoxylin and eosin (H&E).  Sub-gross images of 
H&E stained lung tissue sections were captured at low magnification (1.25x) for measurement of 
tumor burden.  Gross images of all lungs were collected after fixation and prior to histologic 
processing. 
 Tumor burden measurement was performed using Adobe Photoshop CC 2017.1.1 (Adobe 
Systems, San Jose, CA).  Using an image-embedded micrometer, a measurement scale was created 
to designate pixel distance into a logical length (millimeters).  Each lung tumor section was 
measured at both levels for total lung area (mm2) using the Magnetic Lasso tool and total tumor 
area (mm2) using the Magic Wand tool.  Total tumor area was then divided by total lung area per 
section, yielding a % tumor burden per section.  Percent total tumor burden per mouse was also 
calculated as the summation of tumor area in all sections and levels divided by the total summation 





 Five-micron tissue sections cut from lung lobes set in formalin-fixed paraffin-embedded 
blocks were stained for either Factor VIII (A0082) or F4/80 (cs70076) using standard procedures 
at the University of Illinois Veterinary Diagnostic Laboratory.  Factor VIII antibody was used at a 
dilution of 1:1000 and F4/80 antibody at dilution of 1:700. 
 
Survival Curves 
 Mice within survival curve experiments were monitored daily after tail vein injection for 
morbidity and mortality associated with OSA metastasis to the lungs.  Mice were censored if they 
experienced death or were euthanized due to factors unrelated to OSA pulmonary metastasis.  Mice 
experiencing atypically prolonged or shortened survival relative to group median survival times 
(MST) were removed from analysis given the low percentage (less than 5%), due to failed 
successful tail vein injection technique.  Kaplan-Meier curves were created using GraphPad Prism 
version 7.0a for Mac OS X (GraphPad Software) with day 1 being designated as the day following 
tail vein injection.  For mice experiencing euthanasia, day of death was recorded as the day 
following euthanasia.  For mice experiencing natural death, day of death was recorded as the date 
found dead.  Survival curves were compared in GraphPad Prism using the Log-rank (Mantel-Cox) 
test or the Gehan-Breslow-Wilcoxon test, as appropriate.  Survival times are expressed as the 
median (MST). 
 
Microscopic versus Macroscopic Lung Tumor Burden 
 Mice were injected with 1x106 mycoplasma-negative K7M2 via tail vein (day 0), then 
sacrificed at daily intervals from day 2 through day 7 to evaluate when neoplastic burden in the 
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lung transitioned from a microscopic to macroscopic process.  Lungs were collected and processed 
identically to those collected for lung tumor burden measurement, with the exception of a second 
level being cut in at 200 microns rather than 50 microns.  Representative H&E images of tumor 
metastases were captured at 20x and 50x.  Gross images of the lungs were also captured after 
fixation and prior to histologic processing with a dissecting microscope. 
 
Enzyme-Linked Immunosorbent Assays 
 Murine-specific IFNγ, IL-2, and TNFα were measured with Quantikine ELISA (R&D 
Systems) using serum collected immediately post-euthanasia. 
 
Phagocytosis Assays 
 Two murine immune cells lines (J774, RAW) and two canine immune cell lines (DH82, 
Nike) were treated with CpG ODN 2395 for 1, 12, or 24 hours, then phagocytosis was measured 
using the Vybrant Phagocytosis Assay Kit (Invitrogen) according to manufacturer’s instructions. 
 
Statistical Analysis 
 Statistical analysis was performed with GraphPad Prism version 7.0a for Mac OS X 
(GraphPad Software) with significance set at p < 0.05.  All data is expressed as the mean ± SEM.  
Normality was assessed with the Shapiro-Wilk test.  Tumor burden, cytokine, phagocytosis, and 
liposomal clodronate data were analyzed using one-way ANOVA with Tukey’s for parametric 
data and the Kruskal-Wallis test with Dunn’s for non-parametric data.  Cytotoxicity data was 
assessed with repeated measures ANOVA and Tukey’s post-test.  For all data, *p < 0.05, **p < 





Prophylactic TLR Treatment Reduces OS Lung Metastatic Burden and Prolongs Survival Time 
 To assess the activity of our 3 selected TLR agonists (Pam3CSK4, Poly(I:C), and CpG 
ODN 2395) in a relevant model of murine metastatic OS, we employed a prophylactic treatment 
scheme whereby mice were “vaccinated” weekly over a 4-week period with their assigned TLR 
agonist prior to K7M2 tail vein injection, in an effort to maximize the potential for our TLR 
agonists to optimally stimulate the immune system and increase the likelihood of observing a 
positive effect in regards to metastatic OS lung tumor burden and survival time (Figure 3.1).  In 
addition, we also chose to initially investigate, besides evaluating the efficacy of single agent TLR 
vaccination alone (Figures 3.2-3.5), whether concurrent TLR vaccination along with a K7M2 
tumor cell lysate would be beneficial in enhancing anti-tumor immunity through the induction of 
a more robust adaptive immune response (Figure 3.6). 
 Lung tumor burden from mice receiving single agent therapy and sacrificed at either 14- 
or 21-days post-K7M2 injection showed marked variability in the capacity for TLR agonists to 
exert in vivo efficacy for the prevention of OS metastatic disease (Figures 3.2, 3.4).  Mice 
receiving either single agent Poly(I:C) or CpG ODN 2395 exhibited gross reductions at the 14- 
(Figure 3.2a) and 21-day (Figure 3.4a) time periods, while Pam3CSK4 treated mice had lung 
tumor burden grossly similar to the control mice at both time periods.  Histologically, mice 
receiving CpG ODN 2395 also had markedly decreased total lung tumor burden (Figure 3.2b) and 
decreased tumor burden per lung section (Figure 3.2c) when compared to control mice and 
Pam3CSK4 mice at day 14, corroborating the gross reductions observed.  Similar results were 
noted for Poly(I:C) mice in comparison to control and Pam3CSK4 tumor burden per lung section 
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(Figure 3.2c), however, total tumor burden was not significant when compared to controls, but 
was still decreased in comparison to Pam3CSK4 (Figure 3.2b).  Although grossly, Poly(I:C) and 
CpG ODN 2395 therapies could not be appreciated to have discernable gross differences in tumor 
burden, CpG ODN 2395 therapy did result in lesser amounts of tumor burden per lung section in 
comparison to Poly(I:C) (Figure 3.2c).  Circulating cytokine levels in these mice revealed an 
increase in IFNγ for mice receiving CpG ODN 2395 only (Figure 3.3).  Circulating IL-2 and TNFα 
levels were not different between groups (data not shown).   
  The findings at day 14-post K7M2 injection were similar overall in comparison to day 21 
sacrifice periods (Figure 3.4b, c), with few exceptions.  Total tumor burden for Pam3CSK4 was 
not different comparatively to Poly(I:C) or CpG ODN 2395 at this time point (Figure 3.4b), 
whereas it was increased at day 14.  Another item of interest was that relative Poly(I:C) tumor 
burden per lung section was larger in comparison to CpG ODN 2395 at day 21 (Figure 3.4c) than 
at day 14.  This suggested that the effects of Poly(I:C) in reducing OS lung metastasis may be 
marginal or short-lived, whereas CpG ODN 2395 may have more substantial long term reductions 
in OS lung tumor burden. 
Survival times for Poly(I:C) and CpG ODN 2395 were also significantly prolonged 
compared to controls (Figure 3.5), and this finding was repeatable across 2 separate experiments.  
Poly(I:C) had a minimal prolongation in survival time with a MST of 31 (Figure 3.5a) or 41 days 
(Figure 3.5b) compared to control MST of 25 and 23 days, respectively.  This consistent mild 
increase in survival time may be directly related to the relative elevation of Poly(I:C) lung tumor 
burden that was noted at later points during histologic tumor burden analysis, thus further 
supporting that Poly(I:C)’s efficacy in prevention of OS lung tumor metastatic burden is marginal.  
CpG ODN 2395, on the other hand, exhibited a clinically relevant increase in survival time of 
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approximately 3.7x in comparison to controls, regardless of survival experiment, with a MST of 
111 days (Figure 3.5a) and 99 days (Figure 3.5b), compared to MST of 25 and 33 days for 
controls, respectively.  CpG ODN 2395 survival times were also significantly increased compared 
to Poly(I:C) survival (p = 0.01 for survival curves).  Pam3CSK4 did not extend survival time 
relative to controls in either experiment. 
While single agent therapy with CpG ODN 2395 clearly reduces OS metastatic tumor 
burden within the lungs and increases survival time to a clinically relevant level, we wondered if 
concurrent vaccination with a sterile K7M2 tumor cell lysate would influence survival times 
through priming of the immune system with tumor-associated antigens and hence augment a robust 
adaptive immune response (Figure 3.6).  While gross reductions in lung tumor burden (Figure 
3.6a) were similar in conjunction with K7M2 tumor cell lysate for Poly(I:C) and CpG ODN 2395, 
an apparent increase in the Pam3CSK4 + lysate group was noted in comparison to the lysate only 
group.  This was also characterized by significant increases in tumor burden per lung section for 
Pam3CSK4 + lysate in comparison to both the control and lysate only groups (Figure 3.6c), but 
was not appreciable on a total tumor burden level (Figure 3.6b) and did not change survival time 
relative to the control group (Figure 3.6c).  Survival time trends were also similar to single agent 
therapy results amongst the individual agonists (Figure 3.6c), although the MST for Poly(I:C) + 
lysate (53 days) was approximately 23 days longer than the average of single agent therapy 
(average of 36 days).  CpG ODN 2395 + lysate MST was conversely blunted by 32 days (73 day 
MST v. average 105 days for single agent therapy).  K7M2 tumor cell lysate alone also appeared 
to have a mild effect on survival time (MST of 34 days v. 25 days for control).  While it was 
considered too laborious and impracticable from a clinical aspect to pursue concurrent lysate 
treatment in future experiments, concurrent tumor lysate vaccination with TLR agonists do not 
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clearly improve upon anti-cancer activities, which suggests an augmented adaptive immune 
response may not be the underlying reason for enhanced survival time in some of the treatment 
groups. 
 
CpG ODN Promotes a CTL and Th1 Response in Tumor-Bearing Mice 
 In addition to evaluating tumor burden and survival secondary to TLR agonist treatment, 
we also sought to characterize the anti-tumor immune response in TLR-treated, OS-bearing mice 
through evaluation of splenocyte lymphocyte subpopulations via flow cytometry at day 14 and 28 
post-K7M2 injection (Figures 3.7-3.8) as well as ex vivo cytotoxicity assays from splenocytes 
harvested 14 days after tumor injection (Figure 3.9).  Splenic weight was consistently increased 
in CpG ODN 2395 mice compared to controls at both day 14 (Figure 3.7a) and day 28 (Figure 
3.8a); splenic weight was also higher compared to Pam3CSK4 and Poly(I:C) at day 14.  Poly(I:C)  
had an elevated splenic weight compared to controls at day 14, while Pam3CSK4 splenic was 
higher at day 28.  These elevations in splenic weight were often contributed to increased 
mononuclear cell populations, based off Histopaque pellet size and cell counts.  Histologically, all 
spleens were consistent with extramedullary hematopoiesis.  Total spleen count for CD3+/CD8+ 
cytotoxic T lymphocytes (CTLs) (Figure 3.7b) and CD3+/CD8+/CD25+ activated CTLs (Figure 
3.7c) were significantly increased in the CpG ODN 2395 group at day 14; this effect was lost at 
day 28 (Figures 3.8b, c).  CD3+/CD4+/CXCR3+ Th1-polarized T cells were significantly increased 
for CpG ODN 2395 when compared to PamCSK4, but were not elevated compared to controls (p 
= 0.07) (Figure 3.7c).  This effect was also lost at day 28 (Figure 3.8d).  No changes in T 
regulatory lymphocytes (Figures 3.7e and 3.8e) or NK cells (Figures 3.7f and 3.8f) were noted 
for any group at either time point.  From this, CpG ODN 2395 was determined to influence an 
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effector cell response characterized by increased CTLs and Th1 cells, both of which are highly 
recognized as being influential in anti-tumor immunity. 
 We also wondered whether TLR agonist treatment could enhance specific cell-mediated 
cytotoxicity against the K7M2 OS tumor cell line.  To investigate this objective, we cultured 
splenocytes from TLR-treated, OS-bearing mice 14 days after K7M2 tail vein injection and 
subsequently cultured the mononuclear cell population with mitomycin-c treated K7M2 cells for 
7 days in the presence of rmIL-2.  These cells were then employed within an ex vivo cytotoxicity 
assay to determine if the effector cells displayed specific cytotoxicity against K7M2.  The 
Balb/3T3 fibroblast line was used as the non-specific control target.  Poly(I:C) treatment 
significantly increased cytotoxicity at effector:target (E:T) ratios of 25:1, 50:1, and 100:1 
compared to control mice.  However, the cytotoxicity levels were similar between K7M2 and 
Balb/3T3, indicating non-specific cytotoxicity (Figure 3.9b).  Pam3CSK4 also exhibited 
increased non-specific cytotoxicity at the 100:1 E:T ratio (Figure 3.9a).  CpG ODN did not 
statistically increase cytotoxicity at any ratio, but at the 100:1 E:T ratio did start to show some 
divergence from non-treated mice, suggesting CpG ODN 2395 may enhance non-specific 
cytotoxicity at high concentrations (Figure 3.9c).  This suggests that while TLR agonists may 
enhance non-specific cytotoxicity in effector cells, it is unlikely to play a significant role in the 
reduction in metastatic OS lung tumor burden observed with CpG ODN 2395.  We did not further 
investigate if this cytotoxicity was important for the reduction in tumor burden with Poly(I:C). 
 
CpG ODN Therapy May Be Effective in a Setting of Micrometastatic Disease 
 While CpG ODN 2395 appeared to be a promising immunotherapeutic based off our 
findings within the prophylactic treatment scheme, this was an impractical model to assess how 
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CpG ODN 2395 might function in a spontaneous OS setting, where prediction of OS development 
is improbable.  Therefore, we evaluated the administration of CpG ODN 2395 in an “accelerated” 
treatment scheme, where CpG ODN 2395 was given either around the time of K7M2 OS tail vein 
injection or several days after tail vein injection, to better replicate a true canine OS clinical 
scenario, whereby pet dogs present for adjuvant therapeutic management in the micrometastatic 
pulmonary setting. 
 Surprisingly, CpG ODN 2395 given the same day (day 0) as K7M2 tail vein injection 
decreased lung tumor burden and resulted in an approximately 3x increase in survival time when 
compared to control mice, as well as when compared to mice receiving CpG ODN therapy one 
week after tumor injection (Figure 3.10-3.11).  This was apparent not only grossly (Figure 3.10a) 
but also histologically (Figure 3.11b, c).  However, initiating CpG ODN 2395 treatment 7 days 
after tumor cell injection was ineffective at increasing survival time (Figure 3.11), even though 
histologic tumor burden in the day 7 group was decreased compared to controls (Figure 3.10b, c).  
Similarly, intervening with CpG ODN 2395 earlier than day 7 (e.g., day 3 or 5 post-tumor cell 
injection) also did not improve survival time from a clinically-relevant standpoint (Figure 3.11b). 
 Although K7M2 cells injected intravenously reach the lung parenchyma within 1 hour,4 
we were curious if the lack of CpG ODN’s efficacy at later time points correlated with a transition 
from microscopic to macroscopic tumor burden.  To investigate this, we injected naïve mice with 
K7M2 and sacrificed them on a daily basis starting 48 hours after tumor injection.  Macroscopic 
tumor metastases could be observed grossly with magnification starting as early as day 3 after 
tumor injection and became visible to the naked eye by day 5 (Figure 3.12).  Microscopically, 
tumor emboli were easily observed at day 2 and tumor cells also appeared to have extravasated at 
this time (Figure 3.13).  This suspicion was confirmed with Factor VIII immunohistochemistry 
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(images not shown).  As time progressed, metastases became larger and more organized, with 
clearly defined extravasation on H&E by days 3-4.  While we did not investigate CpG ODN 2395 
therapy 1-2 days after tumor cell injection, the timeline of OS tumor progression within the lungs 
suggests CpG ODN 2395’s usefulness may be limited to the very early stages of micrometastatic 
disease, such as initial showering of the lungs with tumor emboli.  This also raises the question of 
whether CpG ODN 2395 exerts its anti-tumor activity in the form of a cell-mediated immune 
response or through non-cellular microenvironment alterations that are not conducive for lung 
metastasis. 
 
Efficacy of CpG ODN is Not Dependent Solely by Macrophages 
 We also sought to elucidate the mechanism of action (MOA) of CpG ODN 2395.  Given 
the apparently narrow window of efficacy for CpG ODN 2395 therapy based off the findings in 
our accelerated treatment scheme, we wondered if macrophage activation and cytotoxic activity 
may be a key MOA, especially given the robust TNFα elucidated by CpG ODN 2395 treatment 
(Chapter II).  Indeed, CpG ODN 2395 treatment enhanced phagocytic activity of the murine 
immune cells J774 and RAW (Figure 3.14a, b), but did not cause consistent increases in 
phagocytic activity within the canine immune cells DH82 and Nike (Figure 3.14c, d).  
Macrophage depletion with liposomal clodronate also failed to negate the efficacy of CpG ODN 
2395 therapy, regardless of intranasal (IN) or intraperitoneal (IP) administration (Figure 3.15).  
Intraperitoneal clodronate therapy markedly decreased splenic weight (Figure 3.16b) and splenic 
macrophage count as analyzed by F4/80 IHC (Figure 3.16c), but coincidentally caused a rebound 
effect in lung macrophages numbers as analyzed by BAL.  Intranasal clodronate also failed to 
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statistically decrease lung macrophage numbers (Figure 3.16a).  This may represent suboptimal 
macrophage depletion levels if the site of CpG ODN’s activity is localized to the lungs.   
 
Discussion 
 These results conclude that the TLR9 agonist CpG ODN 2395 can successfully reduce 
metastatic OS tumor burden in a clinically-relevant murine model of metastatic OS and also is 
most effective in stimulating an immune response in OS-bearing mice, characterized by increased 
circulating IFNγ and increased numbers of Th1 and cytotoxic T cells, making it a reasonable 
candidate TLR agonist for application in dogs with spontaneous OS.  We hypothesized that TLR 
agonists would have variable results in this model, which was supported by the highly divergent 
response between Pam3CSK4, Poly(I:C), and CpG ODN 2395, where Pam3CSK4 appears pro-
tumorigenic, Poly(I:C) appears to have anti-tumorigenic properties initially that are later lost, and 
CpG ODN 2395 has the best overall effect with the largest increase in survival time.  However, 
the results from this chapter also prove the effectiveness of our systematic investigation, which did 
initially suggest CpG ODN 2395 as having the most minimal pro-tumorigenic activity in Chapter 
II.  
 Interestingly, the activity of CpG ODN 2395 is limited to a short time frame between tumor 
cell injection and micrometastasis development, based off observing only mild increases in 
survival time when CpG ODN 2395 was administered starting day 3 after tumor cell injection and 
interpreted in combination with the histologic findings of neoplastic OS cell extravasation into the 
lung parenchyma as early as 48 hours after tumor cell injection in naïve mice.  Ideally, it would be 
interesting to look at CpG ODN 2395’s efficacy at days 1 and 2 post-tumor injection.  If CpG 
ODN 2395 therapy at these time points is also ineffective, then it is possible CpG ODN 2395 is 
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exerting its anti-tumor effects from a cytokine level,5 which may be directly causing cancer cell 
death during metastasis or altering tumor cell expression of metastasis-related genes necessary for 
extravasation into the lung parenchyma.  Based off our data in Chapter II, it is possible CpG ODN 
2395’s effect could be through TNFα release.  CpG ODN 2395’s activity could also be mediated 
by NK cells,6 given the increase in circulating IFNγ in CpG-treated mice, even though we did not 
appreciate increased NK cell splenic numbers.  Alternatively, CpG ODN 2395 may be acting 
directly on OS cells, either through activation of anoikis to prevent metastasis or through inhibition 
of signaling pathways, such as decreased pAkt,7,8 which was observed in K7M2 after treatment 
with CpG ODN 2395 in Chapter II.  Phosphorothioate CpG’s have been shown to inhibit cellular 
adhesion in melanoma9 and if this mechanism is functional in OS, then it may be related to altered 
ezrin or ß4 integrin signaling, both of which are important in OS anoikis resistance.10-12 These 
theories could explain the swift time frame that CpG ODN 2395 appears to function within, since 
it on average takes 4-7 days for an adaptive immune response to develop.13   
While we were unable to show specific cell-mediated cytotoxicity was triggered by CpG 
ODN 2395 and that macrophages are unlikely to be the sole critical component to CpG ODN 
2395’s efficacy, we still cannot definitely conclude that the anti-tumor response observed is not 
directly cell-mediated, even though the elicited response is apparently swift in our accelerated 
model of CpG ODN 2395 therapy.  We specifically chose to explore whether macrophage 
depletion would reverse the effects of CpG ODN 2395, as macrophages can not only be directly 
cytotoxic to tumor cells,14 but also promote adaptive anti-tumor immunity and active innate NK 
cells.15,16  While we observed no reversal of lung tumor burden with macrophage depletion using 
liposomal clodronate, it is questionable as to whether our macrophage depletion was adequate, 
given the lack of significant depletion of splenic macrophages in the IN group and the rebound 
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effect observed in BAL macrophages in the IP group.  To better explore the cell-mediated role of 
CpG ODN 2395 in prevention of OS lung metastasis, additional immune cell depletion studies 
would need to be performed and may be essential for a better understanding of CpG ODN 2395’s 



















FIGURES AND TABLE 
 























Table 3.1: Antibody-fluorochrome conjugates used for the assessment of specific splenic 
lymphocyte subpopulations. 
Three-color flow cytometry for splenic lymphocyte subpopulations included evaluation of 















Figure 3.1: Prophylactic TLR treatment scheme utilized within a clinically-relevant 
murine model of metastatic OS. 
Mice were injected weekly with a single TLR agonist ± K7M2 tumor cell lysate for 4 weeks 
prior to K7M2 tail vein injection.  Two additional weekly treatments were then administered 
prior to sacrifice at day 14 post-K7M2 injection.  Mice that were sacrificed at later time-points 
(e.g., day 21 or day 28) received additional weekly treatments up until the time of sacrifice. 
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Figure 3.2: Prophylactic TLR tumor burden at day 14 post-K7M2 injection. 
(A) Mouse lungs infused with India ink and fixed with Fekete’s solution.  Tumor metastases are 
visualized in white.  (B) Total tumor and (C) tumor burden per lung section as measured 
histologically.  Poly(I:C) and CpG ODN 2395 both visibly and histologically decrease metastatic 
OS lung tumor burden, while Pam3CSK4 tumor burden is comparatively increased.  One-way 



































Figure 3.3: Circulating IFNγ levels in mice within the prophylactic TLR treatment scheme 
at day 14 post-K7M2 injection. 
IFNγ is only elevated in mice receiving CpG ODN therapy.  No differences in circulating IL-2 










































































Figure 3.4: Prophylactic TLR tumor burden at day 21 post-K7M2 injection. 
(A) Mouse lungs infused with India ink and fixed with Fekete’s solution.  Tumor metastases 
are visualized in white.  (B) Total tumor and (C) tumor burden per lung section as measured 
histologically.  Similar results are observed in comparison to day 14 sacrifice periods; however, 
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Figure 3.5: Survival curves for prophylactic TLR treatment. 
(A) Initial and (B) repeat survival curves.  Poly(I:C) and CpG ODN 2395 consistently increase 
survival compared to controls, but the MST (111 and 99 days) reached by CpG ODN 2395 is 
clinically relevant, whereas the MST (31 and 41 days) reached by Poly(I:C) is not.  CpG ODN 
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Figure 3.6: Survival curves for prophylactic TLR + K7M2 tumor lysate treatment. 
(A) Mouse lungs infused with India ink and fixed with Fekete’s solution.  Tumor metastases 
are visualized in white.  (B) Total tumor and (C) tumor burden per lung section as measured 
histologically.  (D) Survival of TLR + tumor lysate groups.  Tumor burden trends and survival 
are similar to single agent TLR therapy, but lysate therapy appears to have divergent effects 










































































































































































































Figure 3.7: Splenic lymphocyte subpopulations at 14 days post-K7M2 injection. 
(A) Splenic weight is significantly higher for Poly(I:C) and CpG ODN 2395 
compared to controls.  CTLs (B), activated CTLs (C), and Th1-polarized T cells (D) 
are increased only with CpG ODN 2395 therapy.  Tregs (E) and NK cells (F) are not 





































































































































































































Figure 3.8: Splenic lymphocyte subpopulations at 28 days post-K7M2 injection. 
(A) Splenic weight is significantly higher for Pam3CSK4 and CpG ODN 2395 
compared to controls.  Most effects seen at day 14 are lost, with CTLs (B) for CpG 
ODN 2395 only being increased compared to Pam3CSK4.  Activated CTLs (C), Th1-
polarized T cells (D), Tregs (E), and NK cells (F) do not different between groups.  
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Figure 3.9: Ex vivo cytotoxicity assays from splenocytes collected at day 14 post-K7M2 
injection under the prophylactic TLR treatment scheme. 
(A) Pam3CSK4 and (B) Poly(I:C) both show increased cytotoxicity compared to untreated 
controls, but this cytotoxicity is non-specific in nature.  (C) CpG ODN 2395 does not 
significantly increase cytotoxicity, although an increased trend is observed.  Repeated measures 
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Figure 3.10: Accelerated CpG ODN 2395 tumor burden. 
CpG ODN 2395 retains efficacy in the reduction of OS lung tumor burden when given the same 
day as K7M2 injection, but the effect is partially lost when treatment starts one week after tumor 
injection. (A) Gross tumor burden visualized via India ink and Fekete’s fixation.  (B) Total 






Figure 3.11: Accelerated CpG ODN 2395 survival. 
(A) Initial and (B) repeat survival curves.  CpG ODN significantly increases survival compared 
to controls when administered on the same day as K7M2-injection, but does not impart 
clinically-relevant increases in survival when intervention occurs at day 3, 5, or 7 post-tumor 
injection.  *p<0.05 and **p<0.01 
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Figure 3.14: CpG ODN 2395 enhances phagocytosis in murine immune cells. 
Murine immune cells (A) J774 and (B) RAW exhibit increased levels of phagocytosis with 
varying concentration and incubation times in response to CpG ODN 2395 treatment.  Canine 
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CpG ODN Only 
Figure 3.15: Clodronate depletion of macrophages does not reverse the effect of CpG 
ODN 2395 in reducing lung metastases. 
Macrophage depletion with liposomal clodronate does not reverse the reduction of lung 
tumor burden observed with CpG ODN 2395 therapy, regardless of the route of clodronate 




Figure 3.16: Effectiveness of clodronate on macrophage depletion. 
Clodronate does not statistically decrease lung macrophages compared to controls, although 
decreases were observed with intranasal administration (A).  Splenic weight (B) and splenic 
macrophages (C) were markedly decreased in mice treated with intraperitoneal clodronate, which 
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EVALUATION OF THE SAFETY AND IMMUNOBIOLOGIC ACTIVITY OF SINGLE 
DOSE CPG ODN 2395 IN PET DOGS WITH SPONTANEOUS OSTEOSARCOMA 
 
Abstract 
 CpG ODNs are synthetic oligonucleotides composed of unmethylated CpG dinucleotides, 
or CpG motifs, which are recognized by TLR9 as indicative of bacterial infection, due to their 
much higher frequency in bacterial DNA compared to mammalian DNA.  This recognition 
subsequently stimulates a profound inflammatory response characterized by the activation of 
plasmacytoid dendritic cells, release of pro-inflammatory cytokines, and ultimately activation of 
a Th1-polarized T cell response. In Chapters II and III we confirmed the ability of CpG ODN 
2395 to shape an anti-tumor immune response while minimizing pro-inflammatory 
tumorigenesis, along with identifying its potent ability to reduce metastatic OS lung tumor 
burden in a relevant murine model of metastatic OS.  These findings encouraged us to pursue 
whether CpG ODN 2395 was worthy of investigation in pet dogs with spontaneous OS as a 
possible cancer immunotherapeutic. 
Before proceeding to a full-scale clinical trial, we employed a small-scale dose-escalation 
study to evaluate whether a single dose of CpG ODN 2395 was safe for OS-bearing dogs and 
could elicit a measurable immune response with diagnostic tests easily available in a clinical 
oncology setting.  Here we show that up to a single 2.0 mg dose of CpG ODN 2395 is tolerable 
in dogs with spontaneous appendicular OS and exhibits no apparent acute or long-term toxicity.  
Additionally, a 2.0 mg dose of CpG ODN 2395 generates measurable immunobiologic read-outs 
consistent with an early innate response characterized by inflammation, as measured by elevated 
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CRP and a probable mild inflammatory leukogram, then transitioning into an adaptive response 
characterized by elevated IL-2 at one-week post-treatment.  These positive results form the 
impetus for further investigation of CpG ODN 2395 within a large-scale canine OS clinical trial 
that also evaluates whether CpG ODN 2395 has therapeutic efficacy in OS-bearing dogs. 
 
Introduction 
CpG ODN 2395 is a synthetic class C oligonucleotide with murine and human TLR9 
activity.1  CpG ODN’s mimic bacterial DNA CpG motifs, thereby serving as the ligand for 
TLR9, whose main function is to recognize bacterial and viral DNA.  Class C CpG’s stimulate 
IFNα production from plasmacytoid dendritic cells (which is important for NK cell activation), 
induce antigen-presenting cell (APC) maturation, and directly activate B cells.  Therefore, Class 
C CpG’s are considered more immunostimulatory than either Class A (or D) or Class B (or K) 
CpG’s which function either primarily in the induction of IFNα secretion (Class A) or B cell 
stimulation (Class B).2-4  This advanced immunostimulatory capacity of CpG ODN 2395, along 
with its capability to stimulate TLR9 in both mice and humans, increased the likelihood of this 
specific CpG having activity in dogs and was a defining reason why we chose to employ CpG 
ODN 2395 from the beginning of the in vitro studies (Chapter I).   
Based off the profound reduction of lung tumor burden and increased survival time in 
mice receiving the TLR9 agonist CpG ODN 2395 compared to the TLR1/2 agonist Pam3CSK4 
and the TLR3 agonist Poly(I:C) (Chapter III), CpG ODN 2395 was determined to be a 
rationally justified agonist for evaluation in pet dogs with spontaneous OS.  While we further 
elucidated in Chapter III that CpG ODN 2395 may have a more restricted time frame of activity 
in regard to preventing lung metastasis, this drug may still be clinically relevant in dogs with 
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spontaneous OS who do not yet have appreciable pulmonary metastatic disease.  Therefore, we 
proceeded with a small dose-escalation pilot study to investigate the safety and immunobiologic 
activity of a single dose of CpG ODN 2395 in pet dogs with spontaneous OS, in an effort to 
assess the possible potential of this to drug to be suitable for use in a large scale clinical trial for 
dogs with OS.  We hypothesized that single dose CpG ODN 2395 would produce a measurable 
immune response with minimal adverse effects. 
 
Material and Methods 
Pet Dogs with Spontaneous OS  
 Pet dogs with spontaneous OS were recruited through the University of Illinois College 
of Veterinary Medicine’s Cancer Care Clinic within the Veterinary Teaching Hospital and under 
the guided care of veterinary medical oncologists.  Dogs were eligible for the trial if they met the 
following criteria: 1) had a histologic or cytologic diagnosis of appendicular OS, excluding 
proximal femur lesions, 2) weight ≥ 25 kg, 3) no prior treatment with chemotherapy, radiation 
therapy, or bisphosphonates, and 4) no non-steroidal anti-inflammatory drugs (NSAIDS) 
administered in the previous 7 days prior to starting the trial.  Pet owners received a monetary 
credit for use at the Veterinary Teaching Hospital and were gifted 3 zoledronate treatments, a 
bisphosphonate agent used in the treatment of OS.5,6  Administration of CpG ODN 2395 and 
sample collection procedures were approved by the University of Illinois IACUC. 
 
CpG ODN 2395 Administration and Sample Collection 
 Recruited dogs with spontaneous appendicular OS were administered a single injection of 
CpG ODN 2395 subcutaneously immediately overlying the primary tumor.  Dogs received either 
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a 0.5, 1.0, or 2.0 mg dose of CpG ODN 2395 reconstituted in 0.5 mL of endotoxin-free water.  
Dose determination was based upon serial entry into the trial, in the fashion of a dose-escalation 
study, with a minimum of 4 dogs recruited per dose.  Whole blood was collected for complete 
blood count (CBC), serum biochemistry, and banking of serum and plasma prior to CpG ODN 
2395 treatment (day 0), 24 hours after injection (day 1), and 7 days post-injection (day 7).  Urine 
was also collected for a complete urinalysis at day 0 and day 7.  Fine-needle aspirates of the 
lymph node draining the primary tumor were similarly collected at all three time points, if 
clinically obtainable.  Dogs were monitored for any adverse effects immediately following CpG 
ODN 2395 administration and throughout the 7-day period of the study. 
 
Serum Cytokine Measurement 
 Banked serum stored at -80ºC was evaluated with canine-specific ELISA for C-reactive 
protein (CRP), IFNγ, IL-2, and TNFα.  CRP was measured with Canine C Reactive Protein 
ELISA (Abcam, Cambridge, UK).  IFNγ and TNFα were measured with Canine Quantikine 
ELISA (R&D Systems).  IL-2 was measured with Canine IL-2 ELISA (MyBioSource). 
 
Hematology, Biochemistry, and Urinalysis 
 All samples for CBC, serum biochemistry, and urinalysis were processed on the day of 
collection by standard procedures within the clinical pathology section of the University of 





Lymph Node Cytology 
 Lymph node samples were stained with Wright-Giemsa and evaluated by a board-
certified veterinary clinical pathologist.  Samples were interpreted based off changes in lymphoid 
populations or infiltrating inflammatory cells. 
 
Statistics 
Statistical analysis was performed with GraphPad Prism version 7.0a for Mac OS X 
(GraphPad Software).  Significance was set at p < 0.05.  Cytokine and hematology data were 
analyzed by repeated measures ANOVA and Tukey’s post-test.  Data is represented as the mean 
± SEM.  For all data, *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
Results 
Recruitment of Pet Dogs with Spontaneous OS 
 A total of 13 dogs were recruited, which consisted of 9 spayed females and 4 castrated 
males.  Ages ranged from 6.1 to 14.3 years with a median age of 10 years.  Breeds included 
Alaskan malamute (1), Labrador retriever (1), golden retriever (1), Great Dane (1), Great 
Pyrenees (1), greyhound (2), mixed breed (5), and St. Bernard (1).  Four dogs each were 
recruited for 0.5 and 2.0 mg treatments.  Five dogs were recruited for 1.0 mg treatment.  One dog 
(0.5 mg) did not have blood collected on day 1 and another dog (1.0 mg) did not complete the 
trial; these dogs were excluded from cytokine and hematology analysis.  One dog (2.0 mg) was 
unable to have lymph node aspirates collected at any time during the trial; four other dogs (1 in 
the 0.5 mg group and 3 in the 1.0 mg group) also did not have lymph node aspirates collected at 
each time point. 
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Single Dose CpG ODN 2395 in Dogs with Spontaneous OS Appears Safe 
 No dogs experienced any adverse reactions during the 7-day study period.  Additionally, 
no evidence of acute renal, hepatic, or GI toxicity were noted biochemically and significant life-
threatening hemogram abnormalities were not observed. 
 
 
High-Dose CpG ODN 2395 is Immunostimulatory in Dogs with Spontaneous OS 
CRP was higher for dogs in the 2.0 mg group at day 1 compared to day 0, but was not 
statistically significant (p = 0.07).  The increase in CRP normalized by day 7 in this group.  No 
significant differences were observed for CRP in the 0.5 and 1.0 mg treatment groups (Figure 
4.1a). Additionally, IL-2 was significantly increased at day 7 compared to day 0 in dogs 
receiving the 2.0 mg dose of CpG ODN 2395.  No statistical difference was detected between 
day 1 and day 0 in this group, or at any time point for the 0.5 and 1.0 mg groups (Figure 4.1b).  
IFNγ was below the assay’s limit of detection for the majority of dogs at each time point.  A 
single dog had detectable IFNγ concentrations, but no apparent increase secondary to CpG ODN 
2395 treatment (data not shown).  TNFα was below the assay’s limit of detection for all dogs at 
each time point (data not shown). 
 In addition to the trend towards significant CRP elevations at day 1 and the significantly 
elevated IL-2 at day 7 in the 2.0 mg CpG ODN 2395 group, these dogs also had significant 
increases in their WBC and neutrophil counts on day 1 post-treatment (Figure 4.2b, c).  These 
hemogram changes could be interpreted as a cortisol-induced stress response and were not 
elevated outside of the reference interval, but in conjunction with the trend towards elevated 
CRP at this time point, these changes were suspected to represent mild inflammation.  Toxic 
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neutrophil changes (cytoplasmic basophilia or vacuolation) were also noted in 3 dogs (75%), 
further supporting inflammation.  Monocytes were decreased in the 0.5 mg CpG ODN at day 7 
post-treatment, but was not considered a clinically relevant finding (Figure 4.2e).  Hematocrit, 
lymphocytes, eosinophils, and platelets were not significantly different from baseline for each 
treatment group (Figure 4.2a, d, f, g).  Lymph node cytology also failed to identify any trends 
suggesting overt evidence of inflammation or antigenic stimulation in response to CpG ODN 
2395 therapy within any treatment group, however, many of the lymph nodes were already 
reactive (increased plasma cells) prior to treatment (Table 4.1).  Overall, these results show that 
a single 2.0 mg dose of CpG ODN creates measurable immunobiologic changes characterized by 




 This pilot dose-escalation study reveals that single dose CpG ODN 2395 can be safely 
administered to dogs with spontaneous OS and that a single dose of 2.0 mg CpG ODN 2395 
initiates a measurable inflammatory response characterized by initial elevations in CRP, one of 
the main acute phase proteins (APPs) of the dog,7 along with elevated WBC and neutrophil 
counts consistent with inflammation.  This acute inflammatory response is then followed by a 
late-term elevation in IL-2, indicative of systemic T cell activation.  These results strongly 
suggest CpG ODN 2395 does have an immunostimulatory phenotype in OS-bearing dogs and 
supports further investigations into whether CpG ODN 2395 has clinical efficacy in preventing 
OS lung metastasis. 
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 Although we observed increased CRP in response to 2.0 mg CpG ODN 2395, which 
supported acute inflammation, this change was not statistically significant.  Time to peak CRP 
levels following an inflammatory insult in dogs have been shown to vary anywhere from 24 to 
48 hours.8,9  Thus, our day 1 sampling protocol may have missed peak CRP levels post-CpG 
ODN 2395 injection.  Measurement of serum amyloid A (SAA), the other major canine APP,7 
may help further support our findings of acute inflammation.  TNFα and IFNγ also did not 
increase in response to CpG ODN 2395 treatment, and in nearly all of the patients recruited were 
unmeasurable.  The serum half-lives of most cytokines are short (often <1 hour)10 and in 
combination with only a single dose of CpG ODN 2395, TNFα and IFNγ may have gone 
undetected due to our sampling schedule.  Additionally, dogs with OS have been shown to have 
increased numbers of MDSCs and Tregs, which may be contributing to an immunosuppressive 
state in these patients,11 thereby preventing production of these cytokines through the generation 
of alternatively-activated macrophages (M2) or inhibition of NK and T cells.12  
We also sought to assess the safety of single dose CpG ODN 2395 in OS-bearing dogs. 
While the biodistribution and half-life of CpG ODN 2395 has not been reported, SQ 
administration of a different CpG ODN molecule in rodents at accelerated doses above those 
used for human clinical trials appeared safe and resulted in little long-term accumulation in 
organs such as the kidney.13  Previous evaluation of a CpG ODN in tumor-bearing dogs reported 
minimal adverse effects14 and we expected a single dose of CpG ODN 2395 to be safe, which 
was confirmed with no observed evidence of acute hepatic, renal, or GI toxicity within our study 
dogs, either clinically or biochemically.  However, our numbers are small and additional 
investigations into CpG ODN 2395’s safety profile in dogs should be performed if a large-scale, 
multi-dose study is commissioned.   
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While our findings support our initial hypothesis, this study’s major limitation is its 
evaluation of only single dose CpG ODN 2395.  Future studies utilizing CpG ODN 2395 in OS-
bearing dogs will likely employ an injection strategy similar to those used in our murine studies 
(Chapter III), whereby dogs will receive multiple doses of CpG ODN 2395.  We envision this 
in the setting of 1-2 doses given pre-amputation, followed by 1-2 additional doses given post-
amputation, along with standard of care chemotherapy for canine OS.  While these additional 
doses of CpG ODN 2395 may stimulate a more robust anti-tumor inflammatory response, CpG’s 
also have the potential to induce immunosuppressive cell subsets, such as Tregs,15 which are 
already suspected to be increased in dogs with OS.  Although we observed no change in Tregs 
within our murine studies with up to 6 weekly treatments of CpG ODN 2395, investigating these 
cellular subsets within OS-bearing dogs would be warranted and highly informative in regard to 
how TLR9 agonism influences long-term immune responses in cancer-bearing dogs that may 
already be immunosuppressed.  Multi-dose CpG ODN 2395 may also be associated with 
toxicities not observed with single dose CpG ODN 2395; this too would also need to be 
evaluated and if significant long-term toxicities are noted, weighed against the benefits from any 









FIGURES AND TABLE 
Figure 4.1:  C-reactive protein (CRP) and IL-2 serum levels from pet dogs with 
spontaneous OS administered a single SQ injection of 0.5, 1, or 2 mg CpG ODN 2395.  
Serum was collected pre-treatment (d0), then at 24 hours (d1), and 7 days (d7) post-
treatment.  CRP levels (A) trend towards significance (p=0.07) 24 hours after treatment and 
IL-2 (B) is significantly increased 7 days post-treatment with a single 2 mg injection of CpG 
ODN 2395.  Repeated measures ANOVA.  **p<0.01 









































Figure 4.2:  Hematology values from pet dogs with spontaneous OS administered a 
single SQ injection of 0.5, 1, or 2 mg CpG ODN 2395. 
Blood was collected pre-treatment (d0), then at 24 hours (d1), and 7 days (d7) post-treatment.  
Hematocrit (A), lymphocytes (D), eosinophils (F), and platelets (G) do not change regardless 
of CpG ODN dose.  Monocytes (E) decreased at d7 in the 0.5 mg CpG ODN 2395 group.  
Total white blood cell counts (B) and neutrophils (C) are significantly increased the day after 
a 2 mg dose of CpG ODN 2395 (d1), consistent with an acute inflammatory response.  
Repeated measures ANOVA.  *p<0.05 and **p<0.01 




















































































































































Draining Lymph Node Cytology 
0.5 mg CpG ODN Day 0 Day 1 Day 7 
Dog 1 ND NCED NCED 
Dog 2 Mildly reactive Mildly reactive Hemodilute 
Dog 3 NCED NCED NCED 
Dog 4 Mildly reactive Mildly reactive Mildly reactive 
1.0 mg CpG ODN Day 0 Day 1 Day 7 
Dog 5 Mildly reactive Reactive Mildly reactive 
Dog 6 Hemodilute NCED Reactive 
Dog 7 ND Mildly reactive Mildly reactive 
Dog 8 Mildly reactive Mildly reactive ND 
Dog 9 NCED NCED ND 
2.0 mg CpG ODN Day 0 Day 1 Day 7 
Dog 10 NCED Hemodilute NCED 
Dog 11 Hemodilute Hemodilute NCED 
Dog 12 Reactive + LH Reactive LH 
Dog 13 ND ND ND 
Table 4.1:  Cytologic findings from the draining lymph node of pet dogs with spontaneous 
OS that were given a single SQ injection of CpG ODN 2395. 
Lymph node cytology samples were taken prior to CpG ODN injection (day 0), the day after 
injection (day 1), and then one week after injection (day 7) to assess for evidence of immune 
activation.  No subjective increases in reactivity or inflammation were appreciated consistently 
among any treatment group.  LH= lymphoid hyperplasia; NCED = no cytologic evidence of 
disease; ND = not done, as no sample could be reasonably collected; Hemodilute = sample had 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 The culmination of this research has identified the TLR9 agonist CpG ODN 2395, as a 
highly-relevant potential immunotherapeutic for the treatment of metastatic OS in dogs.  Using a 
top-down, integrated approach,1 we systematically identified 3 potential TLR agonists 
(Pam3CSK4, Poly(I:C), and CpG ODN) for use in a well-validated murine model of metastatic 
OS, utilizing multiple biological read-outs to elucidate these 3 agonists as the most likely to 
promote anti-tumor immunity while concurrently minimizing the potential for tumorigenesis 
(Chapter II).  Interestingly, even at this early stage of investigation, CpG ODN 2395 was 
suspected to be the least pro-tumorigenic of the 3 potential agonists, although we were cognizant 
these findings would not necessarily translate in vivo.  Therefore, these 3 agonists were then 
employed within the K7M2 model of murine metastatic OS, investigating OS lung tumor burden, 
survival time, and effector cell composition and activity in response to TLR agonist therapy 
(Chapter III).  The results from these in vivo murine studies clearly support CpG ODN 2395 as 
having defined and repeatable efficacy in the reduction of OS metastatic lung tumor burden and 
corresponding increases in survival time, along with enhancement of Th1 and CTL lymphocyte 
subpopulations that are important players in anti-tumor immune responses.   
We further identified that CpG ODN 2395 may have utility in a microscopic disease 
setting, which may have clinical relevance in dogs with spontaneous appendicular OS who 
present without concurrent radiographic evidence of lung metastasis.  While we were unable to 
directly determine the mechanism(s) of action (MOA) for CpG ODN 2395 in reducing OS lung 
tumor metastasis, we suspect that CpG ODN’s MOA functions somewhere along the metastatic 
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cascade between tumor embolization within the circulation and the formation of histologically 
apparent micrometastases within the lungs, and may not even be due to a direct cellular immune 
response.  This theory is also supported by the lack of enhanced K7M2-specific ex vivo 
splenocyte cytotoxicity in mice receiving CpG ODN 2395 and no reversal of lung tumor burden 
in mice receiving a macrophage depleting agent, liposomal clodronate.  While CpG ODN 2395 
may not be beneficial in dogs who already have established macrometastases at the time of 
diagnosis, CpG ODN 2395 may be effective in dogs who have no or minimal micrometastatic 
disease that subsequently undergo amputation to remove the source of tumor emboli, thereby 
potentially preventing the formation of new micrometastases in a peri-operative limb amputation 
setting. 
To this effect, we investigated whether CpG ODN 2395 was safe to administer in pet 
dogs with spontaneous appendicular OS and to determine if a single dose of CpG ODN 2395 
could elicit a measurable immunobiologic response, using a dose-escalation study design 
(Chapter IV).  Our results suggest up to a single dose of 2.0 mg CpG ODN 2395 is safe to 
administer in dogs with spontaneous OS without overt clinical, hematological, or biochemical 
evidence of toxicity; this dose also elicited measurable immunobiologic responses such as post-
administration elevation of the acute phase protein CRP and a concurrent mild inflammatory 
leukocyte response, followed by subsequent elevation in IL-2, consistent with T cell activation.  
These findings lend further promise to employing CpG ODN 2395 successfully into a larger-
scale clinical trial in OS dogs, where multi-dose safety, long-term immunobiologic activity, and 
survival analysis of CpG ODN 2395 would be determined.  We envision this clinical trial would 
investigate CpG ODN 2395 in an adjuvant setting, where dogs would receive CpG ODN 2395 in 
a peri-operative setting (both pre- and post-amputation of the OS-bearing limb) followed by 
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standard of care chemotherapy.  This trial encompasses one of the main future directions of this 
study, and we plan on submitting a proposal to obtain funding for this type of clinical trial.  
Ideally, if this larger clinical trial proved fruitful, CpG ODN 2395 may even have the possibility 
of being translated into a therapy for pediatric OS, given the many similarities between canine 
and human OS (Chapter I).2,3  
An additional future direction also lies amongst finding the exact or a critical MOA 
underlying the efficacy of CpG ODN 2395.  Funding has already been obtained to perform a few 
pilot studies investigating other potential MOA’s for CpG ODN 2395, including TNFα blockade 
and adoptive transfer of splenocytes from tumor-bearing, CpG ODN 2395-treated, long-
surviving mice into naïve mice that will be subsequently K7M2-challeneged.  We also seek to 
identify the lowest efficacious dose of CpG ODN 2395 in our murine model of metastatic OS, as 
this may further inform clinical doses for dogs and reduce costs associated with CpG ODN 2395.  
While our research has consistently shown CpG ODN 2395 to be effective at reducing OS lung 
metastasis in our murine model, identifying the MOA and lowest effective dose will help inform 
future studies, including clinical trials, and may open the door to other potential 
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